https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=0
Page 0 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Adult low strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=1
Page 1 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=2
Page 2 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=3
Page 3 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=4
Page 4 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=5
Page 5 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Equaline Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=6
Page 6 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "THRULIFE EXTRA STRENGTH HEADACHE RELIEF"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=7
Page 7 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN"
        "brand_name": [
          "FIRST AID Contains 101 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=8
Page 8 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=9
Page 9 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=10
Page 10 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE"
        "brand_name": [
          "Butalbital, Aspirin, Caffeine and Codeine Phosphate"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, aspirin, caffeine and codeine may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing to an additive effect, if dosage of this product exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, aspirin, caffeine and codeine may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of butalbital, aspirin, caffeine and codeine and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with Butalbital, Aspirin, Caffeine and Codeine in controlled clinical trials, three (0.8%) discontinued treatment because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the Butalbital, Aspirin, Caffeine and Codeine treated patients in controlled clinical trials comparing the combination product to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine and Codeine Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Body System/Adverse Event Butalbital, Aspirin, Caffeine and Codeine (N=382) Placebo N=(377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to butalbital, aspirin, caffeine and codeine while participating in controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving the combination product, the adverse events were not necessarily caused by butalbital, aspirin, caffeine and codeine. Adverse events are classified by body system and frequency. "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. "Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with Butalbital, Aspirin, Caffeine and Codeine, that have been received since market introduction and that were not reported in clinical trials by the patients treated with the combination product, are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: Abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation,sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epitaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations,syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of this product. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=11
Page 11 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN-NSAID, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=12
Page 12 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 5 grain"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=13
Page 13 of 787
        "generic_name": [
          "CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE"
        "brand_name": [
          "Carisoprodol, Aspirin and Codeine Phosphate"
 
      "drug_interactions": [
        "Drug Interactions Carisoprodol: The sedative effect of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended (see WARNINGS, Sedation ). Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate (see CLINICAL PHARMACOLOGY ). Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect of CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown. Aspirin: Clinically important interactions may occur when certain drugs or alcohol are administered concomitantly with aspirin. Alcohol: Concomitant use of aspirin with >= 3 alcoholic drinks may increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Anticoagulants: Concomitant use of aspirin and anticoagulants (e.g., heparin, warfarin, clopidogrel) increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Additionally, aspirin can displace warfarin from protein binding sites, leading to prolongation of the international normalized ratio (INR). Antihypertensives: The concomitant administration of aspirin with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta¬-blockers, and diuretics may diminish the hypotensive effects of these anti-¬hypertensive products due to aspirin's inhibition of renal prostaglandins, which may lead to decreased renal blood flow and increased sodium and fluid retention. Concomitant use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide due to competition at the renal tubule for secretion. Corticosteroids: Concomitant administration of aspirin and corticosteroids may decrease salicylate plasma levels. Methotrexate: Aspirin may enhance the toxicity of methotrexate due to displacement of methotrexate from its plasma protein binding sites and/or reduction of the renal clearance of methotrexate. Nonsteroidal anti-inflammatory drugs (NSAIDs): The concurrent use of aspirin with selective and nonselective NSAIDs increases the risk of serious GI adverse reactions (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Oral Hypoglycemics Agents: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. Products that effect urinary pH: Ammonium chloride and other drugs that acidify the urine can elevate plasma salicylate concentrations. In contrast, antacids, by alkalinizing the urine, may decrease plasma salicylate concentrations. Uricosuric Agents: Salicylates antagonize the uricosuric action of probenecid and sulfinpyrazone. Codeine Phosphate:The sedative effects of codeine phosphate and other CNS depressants (e.g., alcohol, benzodiazepines, other opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously (see WARNINGS, Respiratory Depression and Sedation )."
      "adverse_reactions": [
        "ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Mirror Pharmaceuticals at 1-862-210-8529 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following adverse reactions, which have occurred with the administration of the individual products alone may also occur with the use of Carisoprodol, Aspirin and Codeine Phosphate Tablets. The following events have been reported during post-approval individual use of carisoprodol and aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Carisoprodol: The following events have been reported during post-¬approval use of carisoprodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular: Tachycardia, postural hypotension, and facial flushing (see OVERDOSAGE ). Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures (see OVERDOSAGE ). Gastrointestinal: Nausea, vomiting, and epigastric discomfort. Hematologic: Leukopenia, pancytopenia. Aspirin: TThe most common adverse reactions associated with the use of aspirin have been gastrointestinal, including abdominal pain, anorexia, nausea, vomiting, gastritis, and occult bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions and PRECAUTIONS , Gastrointestinal Adverse Reactions). Other adverse reactions associated with the use of aspirin include elevated liver enzymes, rash, pruritus, purpura, intracranial hemorrhage, interstitial nephritis, acute renal failure, and tinnitus. Tinnitus may be a symptom of high serum salicylate levels (see OVERDOSAGE ). Codeine Phosphate:Nausea, vomiting, constipation, miosis, sedation, dizziness."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=14
Page 14 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=15
Page 15 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=16
Page 16 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=17
Page 17 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Chewable - Aspirin Regimen Low Dose Aspirin Cherry Flavored"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=18
Page 18 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Leader Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=19
Page 19 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=20
Page 20 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=21
Page 21 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=22
Page 22 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Buffered Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=23
Page 23 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=24
Page 24 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID), AND CAFFEINE"
        "brand_name": [
          "Excedrin Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=25
Page 25 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "berkley and jensen migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=26
Page 26 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "BC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=27
Page 27 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Extra Strength Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=28
Page 28 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Extra Strength Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=29
Page 29 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Health Mart Regular Strength Enteric Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=30
Page 30 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=31
Page 31 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "HEALTH SENSE Adult Chewable Low Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=32
Page 32 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=33
Page 33 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Chewable Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=34
Page 34 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "dg health aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=35
Page 35 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=36
Page 36 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "HEALTH SENSE ECPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=37
Page 37 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, ASPIRIN, IBUPROFEN, ISOPROPYL ALCOHOL, BENZOCAINE, SD ALCOHOL, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, ACETAMINOPHEN, DIPHENHYDRAMINE CHLORIDE"
        "brand_name": [
          "ADVENTURE MEDICAL KITS 1-2 PERSON FIRST AID"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=38
Page 38 of 787
        "generic_name": [
          "BAYER ASPIRIN EXTRA STRENGTH"
        "brand_name": [
          "BAYER Aspirin Extra Strength Caplets"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=39
Page 39 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "HEALTH SENSE ASPIRIN 81"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=40
Page 40 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, ISOPROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "ARC FIRST AID Contains 404 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=41
Page 41 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=42
Page 42 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "BC Arthritis"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=43
Page 43 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE"
        "brand_name": [
          "Back and Body Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=44
Page 44 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=45
Page 45 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Womens"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=46
Page 46 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=47
Page 47 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Aspirin Regimen Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=48
Page 48 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Plus Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=49
Page 49 of 787
        "generic_name": [
          "ASPIRIN,CAFFEINE"
        "brand_name": [
          "Bayer Back and Body Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=50
Page 50 of 787
        "generic_name": [
          "ASPIRIN,DIPHENHYDRAMINE CITRATE"
        "brand_name": [
          "Bayer PM"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=51
Page 51 of 787
        "generic_name": [
          "ASPIRIN, SODIUM BICARBONATE, CITRIC ACID TABLET"
        "brand_name": [
          "WinCo Foods Effervescent Antacid and Pain Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=52
Page 52 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Asprin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=53
Page 53 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=54
Page 54 of 787
        "generic_name": [
          "ASPIRIN CHEWABLE"
        "brand_name": [
          "Aspirin Chewable"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=55
Page 55 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin NSAID"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=56
Page 56 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Enteric coated aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=57
Page 57 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=58
Page 58 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Genuine Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=59
Page 59 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE"
        "brand_name": [
          "Blowfish"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=60
Page 60 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOTROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "FIRST AID Contains 404 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=61
Page 61 of 787
        "generic_name": [
          "ASPIRIN 325 MG"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=62
Page 62 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin regular strength regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=63
Page 63 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN"
        "brand_name": [
          "ADVANCED PAIN RELIEVER"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=64
Page 64 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Rx Act headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=65
Page 65 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATEBACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, ISOPROPYL ALCOHOL,BENZOCAINE,ALCOHOL, ASPIRIN"
        "brand_name": [
          "ARC FIRST AID Contains 303 PIECES HARDCASE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=66
Page 66 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN, BENZOCAINE, ALCOHOL, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE"
        "brand_name": [
          "ACME FIRST AID Contains 404 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=67
Page 67 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=68
Page 68 of 787
        "generic_name": [
          "ACETAMINOPHEN AND ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pamprin Max Menstrual Pain Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=69
Page 69 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Advanced Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=70
Page 70 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=71
Page 71 of 787
        "generic_name": [
          "CARISOPRODOL AND ASPIRIN"
        "brand_name": [
          "Carisoprodol and Aspirin"
 
      "drug_interactions": [
        "Drug Interactions Carisoprodol: The sedative effect of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended (see WARNINGS, Sedation). Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate (see CLINICAL PHARMACOLOGY ). Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect of CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown. Aspirin: Clinically important interactions may occur when certain drugs or alcohol are administered concomitantly with aspirin. Alcohol: Concomitant use of aspirin with >= 3 alcoholic drinks may increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Anticoagulants: Concomitant use of aspirin and anticoagulants (e.g., heparin, warfarin, clopidogrel) increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Additionally, aspirin can displace warfarin from protein binding sites, leading to prolongation of the international normalized ratio (INR). Antihypertensives: The concomitant administration of aspirin with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics may diminish the hypotensive effects of these anti-hypertensive products due to aspirin's inhibition of renal prostaglandins, which may lead to decreased renal blood flow and increased sodium and fluid retention. Concomitant use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide due to competition at the renal tubule for secretion. Corticosteroids: Concomitant administration of aspirin and corticosteroids may decrease salicylate plasma levels. Methotrexate: Aspirin may enhance the toxicity of methotrexate due to displacement of methotrexate from its plasma protein binding sites and/or reduction of the renal clearance of methotrexate. Nonsteroidal anti-inflammatory drugs (NSAIDs): The concurrent use of aspirin with selective and nonselective NSAIDs increases the risk of serious GI adverse reactions (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Oral Hypoglycemics Agents: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. Products that effect urinary pH: Ammonium chloride and other drugs that acidify the urine can elevate plasma salicylate concentrations. In contrast, antacids, by alkalinizing the urine, may decrease plasma salicylate concentrations. Uricosuric Agents: Salicylates antagonize the uricosuric action of probenecid and sulfinpyrazone."
      "adverse_reactions": [
        "ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals at 1-201-961-9000 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following adverse reactions which have occurred with the administration of the individual products alone may also occur with the use of Carisoprodol and Aspirin tablets. The following events have been reported during post-approval individual use of carisoprodol and aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Carisoprodol: The following events have been reported during post-approval use of carisoprodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular: Tachycardia, postural hypotension, and facial flushing (see OVERDOSAGE ). Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures (see OVERDOSAGE ). Gastrointestinal: Nausea, vomiting, and epigastric discomfort. Hematologic: Leukopenia, pancytopenia. Aspirin: The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including abdominal pain, anorexia, nausea, vomiting, gastritis, and occult bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions and PRECAUTIONS , Gastrointestinal Adverse Reactions). Other adverse reactions associated with the use of aspirin include elevated liver enzymes, rash, pruritus, purpura, intracranial hemorrhage, interstitial nephritis, acute renal failure, and tinnitus. Tinnitus may be a symptom of high serum salicylate levels (see OVERDOSAGE )."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=72
Page 72 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=73
Page 73 of 787
        "generic_name": [
          "ASPIRIN DELAYED RELEASE TABLETS, 81 MG"
        "brand_name": [
          "Chronic Pain/Fever Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=74
Page 74 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE"
        "brand_name": [
          "Excedrin Migraine"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=75
Page 75 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=76
Page 76 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=77
Page 77 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=78
Page 78 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=79
Page 79 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Leader Cardinal Health Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=80
Page 80 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=81
Page 81 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=82
Page 82 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Rugby Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=83
Page 83 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Medique Pain Off"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=84
Page 84 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=85
Page 85 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine capsules. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=86
Page 86 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Goodys Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=87
Page 87 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pain Reliever Plus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=88
Page 88 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=89
Page 89 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=90
Page 90 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=91
Page 91 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=92
Page 92 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=93
Page 93 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=94
Page 94 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=95
Page 95 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin regular strength regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=96
Page 96 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=97
Page 97 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Smart Sense Migraine Formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=98
Page 98 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "LOW DOSE ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=99
Page 99 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=100
Page 100 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low strength adult"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=101
Page 101 of 787
        "generic_name": [
          "ISOPROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "Protection"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=102
Page 102 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=103
Page 103 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=104
Page 104 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Enteric coated aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=105
Page 105 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "North Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=106
Page 106 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=107
Page 107 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "healthy accents aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=108
Page 108 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Enteric Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=109
Page 109 of 787
        "generic_name": [
          "ASPIRIN AND DIPYRIDAMOLE"
        "brand_name": [
          "aspirin and dipyridamole"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS -Co-administration with anticoagulants, antiplatelets, or NSAIDS can increase risk of bleeding (7.1) -Decreased renal function can occur with co-administration with NSAIDS (7.1) 7.1 Drug Interaction Study Information Obtained From Literature Adenosine Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Angiotensin Converting Enzyme (ACE) Inhibitors Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. Acetazolamide Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. Anticoagulants and Antiplatelets Patients taking aspirin and extended release dipyridamole capsules in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Diuretics The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Methotrexate Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function. Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. Uricosuric Agents (probenecid and sulfinpyrazone) Salicylates antagonize the uricosuric action of uricosuric agents."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: -Hypersensitivity [see Contraindications (4.1) ]. -Allergy [see Contraindications (4.2) ]. -Risk of Bleeding [see Warnings and Precautions (5.1) ]. -The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea (6) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The efficacy and safety of aspirin and extended release dipyridamole capsules was established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either aspirin and extended release dipyridamole capsules, aspirin, ER-DP, or placebo [see Clinical Studies (14) ]; primary endpoints included stroke (fatal or nonfatal) and death from all causes. This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of aspirin and extended release dipyridamole capsules with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization. Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with aspirin and extended release dipyridamole capsules where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety. Table 1 Incidence of Adverse Events in ESPS2* Individual Treatment Group Body System/Preferred Term ASA/ER-DP ER-DP Alone ASA Alone Placebo * Reported by >=1% of patients during aspirin and extended release dipyridamole capsules treatment where the incidence was greater than in those treated with placebo. Note: ASA/ER-DP = aspirin 25 mg/extended release dipyridamole 200 mg; ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID NOS = not otherwise specified. Total Number of Patients 1650 1654 1649 1649 Total Number (%) of Patients With at Least One On-Treatment Adverse Event 1319 (80%) 1305 (79%) 1323 (80%) 1304 (79%) Central and Peripheral Nervous System Disorders Headache 647 (39%) 634 (38%) 558 (34%) 543 (33%) Convulsions 28 (2%) 15 (1%) 28 (2%) 26 (2%) Gastrointestinal System Disorders Dyspepsia 303 (18%) 288 (17%) 299 (18%) 275 (17%) Abdominal Pain 289 (18%) 255 (15%) 262 (16%) 239 (14%) Nausea 264 (16%) 254 (15%) 210 (13%) 232 (14%) Diarrhea 210 (13%) 257 (16%) 112 (7%) 161 (10%) Vomiting 138 (8%) 129 (8%) 101 (6%) 118 (7%) Hemorrhage Rectum 26 (2%) 22 (1%) 16 (1%) 13 (1%) Melena 31 (2%) 10 (1%) 20 (1%) 13 (1%) Hemorrhoids 16 (1%) 13 (1%) 10 (1%) 10 (1%) GI Hemorrhage 20 (1%) 5 (0%) 15 (1%) 7 (0%) Body as a Whole - General Disorders Pain 105 (6%) 88 (5%) 103 (6%) 99 (6%) Fatigue 95 (6%) 93 (6%) 97 (6%) 90 (5%) Back Pain 76 (5%) 77 (5%) 74 (4%) 65 (4%) Accidental Injury 42 (3%) 24 (1%) 51 (3%) 37 (2%) Malaise 27 (2%) 23 (1%) 26 (2%) 22 (1%) Asthenia 29 (2%) 19 (1%) 17 (1%) 18 (1%) Syncope 17 (1%) 13 (1%) 16 (1%) 8 (0%) Psychiatric Disorders Amnesia 39 (2%) 40 (2%) 57 (3%) 34 (2%) Confusion 18 (1%) 9 (1%) 22 (1%) 15 (1%) Anorexia 19 (1%) 17 (1%) 10 (1%) 15 (1%) Somnolence 20 (1%) 13 (1%) 18 (1%) 9 (1%) Musculoskeletal System Disorders Arthralgia 91 (6%) 75 (5%) 91 (6%) 76 (5%) Arthritis 34 (2%) 25 (2%) 17 (1%) 19 (1%) Arthrosis 18 (1%) 22 (1%) 13 (1%) 14 (1%) Myalgia 20 (1%) 16 (1%) 11 (1%) 11 (1%) Respiratory System Disorders Coughing 25 (2%) 18 (1%) 32 (2%) 21 (1%) Upper Respiratory Tract Infection 16 (1%) 9 (1%) 16 (1%) 14 (1%) Cardiovascular Disorders, General Cardiac Failure 26 (2%) 17 (1%) 30 (2%) 25 (2%) Platelet, Bleeding and Clotting Disorders Hemorrhage NOS 52 (3%) 24 (1%) 46 (3%) 24 (1%) Epistaxis 39 (2%) 16 (1%) 45 (3%) 25 (2%) Purpura 23 (1%) 8 (0%) 9 (1%) 7 (0%) Neoplasm Neoplasm NOS 28 (2%) 16 (1%) 23 (1%) 20 (1%) Red Blood Cell Disorders Anemia 27 (2%) 16 (1%) 19 (1%) 9 (1%) Discontinuation due to adverse events in ESPS2 was 25% for aspirin and extended release dipyridamole capsules, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2) Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of >=1% in the Aspirin and Extended Release Dipyridamole Capsules Group Treatment Groups ASA/ER-DP ER-DP ASA Placebo Note: ASA/ER-DP = aspirin 25 mg/extended release dipyridamole 200 mg; ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID Total Number of Patients 1650 1654 1649 1649 Patients with at least one Adverse Event that led to treatment discontinuation 417 (25%) 419 (25%) 318 (19%) 352 (21%) Headache 165 (10%) 166 (10%) 57 (3%) 69 (4%) Dizziness 85 (5%) 97 (6%) 69 (4%) 68 (4%) Nausea 91 (6%) 95 (6%) 51 (3%) 53 (3%) Abdominal Pain 74 (4%) 64 (4%) 56 (3%) 52 (3%) Dyspepsia 59 (4%) 61 (4%) 49 (3%) 46 (3%) Vomiting 53 (3%) 52 (3%) 28 (2%) 24 (1%) Diarrhea 35 (2%) 41 (2%) 9 (<1%) 16 (<1%) Stroke 39 (2%) 48 (3%) 57 (3%) 73 (4%) Transient Ischemic Attack 35 (2%) 40 (2%) 26 (2%) 48 (3%) Angina Pectoris 23 (1%) 20 (1%) 16 (<1%) 26 (2%) Headache was most notable in the first month of treatment. Other Adverse Events Adverse reactions that occurred in less than 1% of patients treated with aspirin and extended release dipyridamole capsules in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below. Body as a Whole: Allergic reaction, fever Cardiovascular: Hypotension Central Nervous System: Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage Gastrointestinal: Gastritis, ulceration and perforation Hearing and Vestibular Disorders: Tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism Heart Rate and Rhythm Disorders: Tachycardia, palpitation, arrhythmia, supraventricular tachycardia Liver and Biliary System Disorders: Cholelithiasis, jaundice, hepatic function abnormal Metabolic and Nutritional Disorders: Hyperglycemia, thirst Platelet, Bleeding and Clotting Disorders: Hematoma, gingival bleeding Psychiatric Disorders: Agitation Reproductive: Uterine hemorrhage Respiratory: Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edema Special Senses Other Disorders: Taste loss Skin and Appendages Disorders: Pruritus, urticaria Urogenital: Renal insufficiency and failure, hematuria Vascular (Extracardiac) Disorders: Flushing Laboratory Changes Over the course of the 24-month study (ESPS2), patients treated with aspirin and extended release dipyridamole capsules showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm3. 6.2 Post-Marketing Experience The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to aspirin and extended release dipyridamole capsules. Body as a Whole: Hypothermia, chest pain Cardiovascular: Angina pectoris Central Nervous System: Cerebral edema Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia Gastrointestinal: Pancreatitis, Reye syndrome, hematemesis Hearing and Vestibular Disorders: Hearing loss Immune System Disorders: Hypersensitivity, acute anaphylaxis, laryngeal edema Liver and Biliary System Disorders: Hepatitis, hepatic failure Musculoskeletal: Rhabdomyolysis Metabolic and Nutritional Disorders: Hypoglycemia, dehydration Platelet, Bleeding and Clotting Disorders: Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia Reproductive: Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding Respiratory: Tachypnea, dyspnea Skin and Appendages Disorders: Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematoma Urogenital: Interstitial nephritis, papillary necrosis, proteinuria Vascular (Extracardiac Disorders): Allergic vasculitis Other Adverse Events: anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS -Aspirin and Extended Release Dipyridamole Capsules increases the risk of bleeding (5.1) -Avoid use in patients with severe hepatic or renal insufficiency (5.2, 5.3) -Can cause fetal harm when administered to a pregnant woman, especially in the third trimester (5.4) 5.1 Risk of Bleeding Aspirin and Extended Release Dipyridamole Capsules increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug Interactions (7.1) ]. Intracranial Hemorrhage In ESPS2 the incidence of intracranial hemorrhage was 0.6% in the Aspirin and Extended Release Dipyridamole Capsules group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups. Gastrointestinal (GI) Side Effects GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur. In ESPS2 the incidence of gastrointestinal bleeding was 4.1% in the Aspirin and Extended Release Dipyridamole Capsules group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups. Peptic Ulcer Disease Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding. Alcohol Warning Because Aspirin and Extended Release Dipyridamole Capsules contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. 5.2 Renal Failure Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.3 Hepatic Insufficiency Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.4 Pregnancy Because Aspirin and Extended Release Dipyridamole Capsules contains aspirin, Aspirin and Extended Release Dipyridamole Capsules can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid Aspirin and Extended Release Dipyridamole Capsules in the third trimester of pregnancy [see Use in Specific Populations (8.1) ]. Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m2 basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of Aspirin and Extended Release Dipyridamole Capsules. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of Aspirin and Extended Release Dipyridamole Capsules in pregnant women. If Aspirin and Extended Release Dipyridamole Capsules is used during pregnancy, or if the patient becomes pregnant while taking Aspirin and Extended Release Dipyridamole Capsules, inform the patient of the potential hazard to the fetus. 5.5 Coronary Artery Disease Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole. For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications. 5.6 Hypotension Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension. 5.7 General Aspirin and Extended Release Dipyridamole Capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=110
Page 110 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Safety Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=111
Page 111 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "good neighbor pharmacy migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=112
Page 112 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Goodys Cool Orange"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=113
Page 113 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=114
Page 114 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Pain Away Plus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=115
Page 115 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "EC-81Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=116
Page 116 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Ecotrin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=117
Page 117 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=118
Page 118 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=119
Page 119 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=120
Page 120 of 787
        "generic_name": [
          "OXYCODONE AND ASPIRIN"
        "brand_name": [
          "ENDODAN"
 
      "drug_interactions": [
        "Drug/Drug Interactions with Oxycodone Opioid analgesics may enhance the neuromuscular-blocking action of skeletal muscle relaxants and produce an increase in the degree of respiratory depression. Patients receiving CNS depressants such as other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, centrally-acting anti-emetics, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with ENDODAN tablets may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, naltrexone, and butorphanol) should be administered with caution to a patient who has received or is receiving a pure opioid agonist such as oxycodone. These agonist/antagonist analgesics may reduce the analgesic effect of oxycodone or may precipitate withdrawal symptoms. Drug/Drug Interactions with Aspirin Angiotensin Converting Enzyme (ACE) Inhibitors: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due to its indirect effect on the renin-angiotensin conversion pathway. Acetazolamide: Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. Anticoagulant Therapy (Heparin and Warfarin): Patients on anticoagulation therapy are at increased risk for bleeding because of drug-drug interactions and the effect on platelets. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. Anticonvulsants: Salicylate can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. Beta Blockers: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. Diuretics: The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Methotrexate: Aspirin may enhance the serious side and toxicity of methotrexate due to displacement from its plasma protein binding sites and/or reduced renal clearance. Nonsteroidal Anti-inflammatory Drugs (NSAID's): The concurrent use of aspirin with other NSAID's should be avoided because this may increase bleeding or lead to decreased renal function. Aspirin may enhance the serious side effects and toxicity of ketorolac, due to displacement from its plasma protein binding sites and/or reduced renal clearance. Oral Hypoglycemics Agents: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. Uricosuric Agents: Salicylates antagonize the uricosuric action of probenecid or sulfinpyrazone. Drug/Laboratory Test Interactions Depending on the sensitivity/specificity and the test methodology, the individual components of ENDODAN tablets may cross-react with assays used in the preliminary detection of cocaine (primary urinary metabolite, benzoylecgonine) or marijuana (cannabinoids) in human urine. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. The preferred confirmatory method is gas chromatography/mass spectrometry (GC/MS). Moreover, clinical considerations and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used. Salicylates may increase the protein bound iodine (PBI) result by competing for the protein binding sites on pre-albumin and possibly thyroid-binding globulins."
      "adverse_reactions": [
        "ADVERSE REACTIONS Serious adverse reactions that may be associated with ENDODAN tablet use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock (see OVERDOSAGE). The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation and pruritus. Aspirin may increase the likelihood of hemorrhage due to its effect on the gastric mucosa and platelet function. Furthermore, aspirin has the potential to cause anaphylaxis in hypersensitive patients as well as angioedema especially in patients with chronic urticaria. Other adverse reactions due to aspirin use include anorexia, reversible hepatotoxicity, leukopenia, thrombocytopenia, purpura, decreased plasma iron concentration, and shortened erythrocyte survival time. Other adverse reactions obtained from postmarketing experiences with ENDODAN tablets are listed by organ system and in decreasing order of severity and/or frequency as follows: Body as a Whole allergic reaction, malaise, asthenia, headache, anaphylaxis, fever, hypothermia, thirst, increased sweating, accident, accidental overdose, non-accidental overdose. Cardiovascular tachycardia, dysrhythmias, hypotension, orthostatic hypotension, bradycardia, palpitations Central and Peripheral Nervous System stupor, paresthesia, agitation, cerebral edema, coma, confusion, dizziness, headache, subdural or intracranial hemorrhage, lethargy, seizures, anxiety, mental impairment Fluid and Electrolyte dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis Gastrointestinal hemorrhagic gastric/duodenal ulcer, gastric/peptic ulcer, dyspepsia, abdominal pain, diarrhea, eructation, dry mouth, gastrointestinal bleeding, intestinal perforation, nausea, vomiting, transient elevations of hepatic enzymes, hepatitis, Reye syndrome, pancreatitis, intestinal obstruction, ileus Hearing and Vestibular hearing loss, tinnitus. Patients with high frequency loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism. Hematologic unspecified hemorrhage, purpura, reticulocytosis, prolongation of prothrombin time, disseminated intravascular coagulation, ecchymosis, thrombocytopenia. Hypersensitivity acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction Metabolic and Nutritional hypoglycemia, hyperglycemia, acidosis, alkalosis Musculoskeletal rhabdomyolysis Ocular miosis, visual disturbances, red eye. Psychiatric drug dependence, drug abuse, somnolence, depression, nervousness, hallucination Reproductive prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding, closure of patent ductus arteriosis Respiratory System bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema Skin and Appendages urticaria, rash, flushing Urogenital interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=121
Page 121 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Genuine Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=122
Page 122 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN LOW DOSE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=123
Page 123 of 787
        "generic_name": [
          "CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE"
        "brand_name": [
          "Carisoprodol, Aspirin and Codeine Phosphate"
 
      "drug_interactions": [
        "Drug Interactions Carisoprodol: The sedative effect of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended (see WARNINGS, Sedation ). Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate (see CLINICAL PHARMACOLOGY ). Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect of CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown. Aspirin: Clinically important interactions may occur when certain drugs or alcohol are administered concomitantly with aspirin. Alcohol: Concomitant use of aspirin with >= 3 alcoholic drinks may increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Anticoagulants: Concomitant use of aspirin and anticoagulants (e.g., heparin, warfarin, clopidogrel) increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Additionally, aspirin can displace warfarin from protein binding sites, leading to prolongation of the international normalized ratio (INR). Antihypertensives: The concomitant administration of aspirin with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics may diminish the hypotensive effects of these anti-hypertensive products due to aspirin's inhibition of renal prostaglandins, which may lead to decreased renal blood flow and increased sodium and fluid retention. Concomitant use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide due to competition at the renal tubule for secretion. Corticosteroids: Concomitant administration of aspirin and corticosteroids may decrease salicylate plasma levels. Methotrexate: Aspirin may enhance the toxicity of methotrexate due to displacement of methotrexate from its plasma protein binding sites and/or reduction of the renal clearance of methotrexate. Nonsteroidal anti-inflammatory drugs (NSAIDs): The concurrent use of aspirin with selective and nonselective NSAIDs increases the risk of serious GI adverse reactions (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Oral Hypoglycemics Agents: Aspirin may increase the serum glucose lowering action of insulin and sulfonylureas leading to hypoglycemia. Products that effect urinary pH: Ammonium chloride and other drugs that acidify the urine can elevate plasma salicylate concentrations. In contrast, antacids, by alkalinizing the urine, may decrease plasma salicylate concentrations. Uricosuric Agents: Salicylates antagonize the uricosuric action of probenecid and sulfinpyrazone. Codeine Phosphate: The sedative effects of codeine phosphate and other CNS depressants (e.g., alcohol, benzodiazepines, other opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously (see WARNINGS, Respiratory Depression and Sedation )."
      "adverse_reactions": [
        "ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals at 1-201-961-9000 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following adverse reactions, which have occurred with the administration of the individual products alone may also occur with the use of Carisoprodol, Aspirin and Codeine Phosphate Tablets. The following events have been reported during post-approval individual use of carisoprodol and aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Carisoprodol: The following events have been reported during post-approval use of carisoprodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular: Tachycardia, postural hypotension, and facial flushing (see OVERDOSAGE ). Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures (see OVERDOSAGE ). Gastrointestinal: Nausea, vomiting, and epigastric discomfort. Hematologic: Leukopenia, pancytopenia. Aspirin: The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including abdominal pain, anorexia, nausea, vomiting, gastritis, and occult bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions and PRECAUTIONS , Gastrointestinal Adverse Reactions). Other adverse reactions associated with the use of aspirin include elevated liver enzymes, rash, pruritus, purpura, intracranial hemorrhage, interstitial nephritis, acute renal failure, and tinnitus. Tinnitus may be a symptom of high serum salicylate levels (see OVERDOSAGE ). Codeine Phosphate: Nausea, vomiting, constipation, miosis, sedation, dizziness."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=124
Page 124 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE"
        "brand_name": [
          "Ascomp with Codeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing addictive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) in controlled clinical trials, three (0.8%) discontinued treatment with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) treated patients in controlled clinical trials comparing ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate, USP Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Body System/Adverse Event Butalbital, Aspirin, Caffeine, and Codeine Phosphate, USP (N=382) Placebo (N=377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), the adverse events were not necessarily caused by ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP). Adverse events are classified by body system and frequency, \"Frequent\" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. \"Infrequent\" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous System: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness and sluggishness. Autonomic Nervous System: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), that have been received since market introduction and that were not reported in clinical trials by the patients treated with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous System: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous System: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP). Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=125
Page 125 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=126
Page 126 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=127
Page 127 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=128
Page 128 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Sunmark aspirin low dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=129
Page 129 of 787
        "generic_name": [
          "CARISOPRODOL AND ASPIRIN"
        "brand_name": [
          "Carisoprodol and Aspirin"
 
      "drug_interactions": [
        "Drug Interactions Carisoprodol: The sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended (see WARNINGS, Sedation ). Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate (see CLINICAL PHARMACOLOGY). Coadministration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown. Aspirin: Clinically important interactions may occur when certain drugs or alcohol are administered concomitantly with aspirin. Alcohol: Concomitant use of aspirin with >= 3 alcoholic drinks may increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Anticoagulants: Concomitant use of aspirin with anticoagulants (e.g., heparin, warfarin, clopidogrel) increases the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Additionally, aspirin can displace warfarin from protein binding sites, leading to prolongation of the international normalized ratio (INR). Antihypertensives: The concomitant administration of aspirin with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics may diminish the hypotensive effects of these anti-hypertensive products due to aspirin's inhibition of renal prostaglandins, which may lead to decreased renal blood flow and increased sodium and fluid retention. Concomitant use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide due to competition at the renal tubule for secretion. Corticosteroids: Concomitant administration of aspirin and corticosteriods may decrease salicylate plasma levels. Methotrexate: Aspirin may enhance the toxicity of methotrexate due to displacement of methotrexate from its plasma protein binding sites and/or reduction of the renal clearance of methotrexate. Nonsteroidal anti-inflammatory drugs (NSAIDs): The concurrent use of aspirin with selective and nonselective NSAIDs increases the risk of serious GI adverse reactions (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Oral Hypoglycemics Agents: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. Products that effect urinary pH: Ammonium chloride and other drugs that acidify the urine can elevate plasma salicylate concentrations. In contrast, antacids, by alkalinizing the urine, may decrease plasma salicylate concentrations. Uricosuric Agents: Salicylates antagonize the uricosuric action of probenecid and sulfinpyrazone."
      "adverse_reactions": [
        "ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Heritage Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following adverse reactions which have occurred with the administration of the individual products alone may also occur with the use of carisoprodol and aspirin tablets. The following events have been reported during post-approval individual use of carisoprodol and aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Carisoprodol: The following events have been reported during post-approval use of carisoprodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular: Tachycardia, postural hypotension, and facial flushing (see OVERDOSAGE ). Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures (see OVERDOSAGE ). Gastrointestinal: Nausea, vomiting, and epigastric discomfort. Hematologic: Leukopenia, pancytopenia. Aspirin: The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including abdominal pain, anorexia, nausea, vomiting, gastritis, and occult bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions and PRECAUTIONS, Gastrointestinal Adverse Reactions ). Other adverse reactions associated with the use of aspirin include elevated liver enzymes, rash, pruritus, purpura, intracranial hemorrhage, interstitial nephritis, acute renal failure, and tinnitus. Tinnitus may be a symptom of high serum salicylate levels (see OVERDOSAGE)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=130
Page 130 of 787
        "generic_name": [
          "ASPIRIN, IBUPROFEN, ACETAMINOPHEN, ALCOHOL, BENZALKONIUM CHLORIDE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE"
        "brand_name": [
          "GFA First Aid Kit Essentials - 33 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=131
Page 131 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Care One Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=132
Page 132 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Vanquish"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=133
Page 133 of 787
        "generic_name": [
          "ANHYDROUS CITRIC ACID, SODIUM BICARBONATE, AND ASPIRIN"
        "brand_name": [
          "Alka-Seltzer XTRA STRENGTH"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=134
Page 134 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID ANHYDROUS, AND SODIUM BICARBONATE"
        "brand_name": [
          "Effervescent Pain Relief Fast Relief Fast Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=135
Page 135 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID MONOHYDRATE, AND SODIUM BICARBONATE"
        "brand_name": [
          "Effervescent Pain Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=136
Page 136 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=137
Page 137 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=138
Page 138 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL,BENZOCAINE,ALCOHOL, ASPIRIN,BACITRACIN ZINC,NEOMYCIN SULFATE,POLYMYXIN B SULFATE"
        "brand_name": [
          "ARC FIRST AID Contains 303 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=139
Page 139 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Adult Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=140
Page 140 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN LOW DOSE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=141
Page 141 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Equaline migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=142
Page 142 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN 325 MG"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=143
Page 143 of 787
        "generic_name": [
          "ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG"
        "brand_name": [
          "Bi Electro Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=144
Page 144 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=145
Page 145 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=146
Page 146 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN 325 MG EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=147
Page 147 of 787
        "generic_name": [
          "BULTABITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital Compound"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=148
Page 148 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, ASPIRIN, IBUPROFEN, ISOPROPYL ALCOHOL, BENZOCAINE, SD ALCOHOL, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, ACETAMINOPHEN"
        "brand_name": [
          "ADVENTURE MEDICAL KITS 1-2 PERSON NATIONAL SKI PATROL FIRST AID"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=149
Page 149 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=150
Page 150 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=151
Page 151 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=152
Page 152 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "leader aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=153
Page 153 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=154
Page 154 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=155
Page 155 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=156
Page 156 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=157
Page 157 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "good sense aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=158
Page 158 of 787
        "generic_name": [
          "ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE"
        "brand_name": [
          "TABCIN 500"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=159
Page 159 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=160
Page 160 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=161
Page 161 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=162
Page 162 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Henry Schein Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=163
Page 163 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=164
Page 164 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=165
Page 165 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Pharbest Regular Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=166
Page 166 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Safety coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=167
Page 167 of 787
        "generic_name": [
          "ACETAMINOPHEN AND ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Goodys Cool Orange Headache"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=168
Page 168 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=169
Page 169 of 787
        "generic_name": [
          "ASPIRIN BUFFERED WITH MAGNESIUM OXIDE"
        "brand_name": [
          "Migralex Dr. Mauskop"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=170
Page 170 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=171
Page 171 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=172
Page 172 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=173
Page 173 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=174
Page 174 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=175
Page 175 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Adult Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=176
Page 176 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=177
Page 177 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=178
Page 178 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Genuine Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=179
Page 179 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=180
Page 180 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Rx Act Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=181
Page 181 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "health mart aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=182
Page 182 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=183
Page 183 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Ecotrin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=184
Page 184 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=185
Page 185 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Alka-Seltzer Plus Cold Formula (Cherry Burst)"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=186
Page 186 of 787
        "generic_name": [
          "OXYCODONE HYDROCHLORIDE AND ASPIRIN"
        "brand_name": [
          "Oxycodone and Aspirin"
 
      "drug_interactions": [
        "Drug/Drug Interactions with Oxycodone CYP3A4 Inhibitors and CYP450 Inducers Oxycodone is extensively metabolized by multiple metabolic pathways. CYP3A4 is the major enzyme involved in noroxycodone formation followed by CYP2B6, CYP2C9/19 and CYP2D6. Drugs that inhibit CYP3A4 activity, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations and prolonged opioid effects. Similarly, CYP450 inducers, such as rifampin, carbamazepine, and phenytoin, may induce the metabolism of oxycodone and, therefore, may cause increased clearance of the drug which could lead to a decrease in oxycodone plasma concentrations, lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. If co-administration with oxycodone and aspirin tablets is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors or CYP450 inducers. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved. Skeletal Muscle Relaxants Opioid analgesics may enhance the neuromuscularblocking action of skeletal muscle relaxants and produce an increase in the degree of respiratory depression. CNS Depressants Patients receiving CNS depressants such as other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, centrally-acting anti-emetics, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone and aspirin tablets may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Analgesics Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, naltrexone, and butorphanol) should be administered with caution to a patient who has received or is receiving a pure opioid agonist such as oxycodone. These agonist/antagonist analgesics may reduce the analgesic effect of oxycodone or may precipitate withdrawal symptoms.",
      "adverse_reactions": [
        "ADVERSE REACTIONS Serious adverse reactions that may be associated with oxycodone and aspirin tablet use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock (see OVERDOSAGE). The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation and pruritus. Aspirin may increase the likelihood of hemorrhage due to its effect on the gastric mucosa and platelet function. Furthermore, aspirin has the potential to cause anaphylaxis in hypersensitive patients as well as angioedema especially in patients with chronic urticaria. Other adverse reactions due to aspirin use include anorexia, reversible hepatotoxicity, leukopenia, thrombocytopenia, purpura, decreased plasma iron concentration, and shortened erythrocyte survival time. Other adverse reactions obtained from post-marketing experiences with oxycodone and aspirin tablets are listed by organ system and in decreasing order of severity and/or frequency as follows: Body as a Whole: allergic reaction, malaise, asthenia, headache, anaphylaxis, fever, hypothermia, thirst, increased sweating, accident, accidental overdose, non-accidental overdose Cardiovascular: tachycardia, dysrhythmias, hypotension, orthostatic hypotension, bradycardia, palpitations Central and Peripheral Nervous System: stupor, paresthesia, agitation, cerebral edema, coma, confusion, dizziness, headache, subdural or intracranial hemorrhage, lethargy, seizures, anxiety, mental impairment Fluid and Electrolyte: dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis Gastrointestinal: hemorrhagic gastric/duodenal ulcer, gastric/peptic ulcer, dyspepsia, abdominal pain, diarrhea, eructation, dry mouth, gastrointestinal bleeding, intestinal perforation, nausea, vomiting, transient elevations of hepatic enzymes, hepatitis, Reye syndrome, pancreatitis, intestinal obstruction, ileus Hearing and Vestibular: hearing loss, tinnitus. Patients with high frequency loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism. Hematologic: unspecified hemorrhage, purpura, reticulocytosis, prolongation of prothrombin time, disseminated intravascular coagulation, ecchymosis, thrombocytopenia Hypersensitivity: acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction Metabolic and Nutritional: hypoglycemia, hyperglycemia, acidosis, alkalosis Musculoskeletal: rhabdomyolysis Ocular: miosis, visual disturbances, red eye Psychiatric: drug dependence, drug abuse, somnolence, depression, nervousness, hallucination Reproductive: prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding, closure of patent ductus arteriosis Respiratory System: bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema Skin and Appendages: urticaria, rash, flushing Urogenital: interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=187
Page 187 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=188
Page 188 of 787
        "generic_name": [
          "REGULAR STRENGTH ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=189
Page 189 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN LOW DOSE CHEWABLE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=190
Page 190 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "leader aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=191
Page 191 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=192
Page 192 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=193
Page 193 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of Butalbital, Aspirin, and Caffeine Capsules, USP. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=194
Page 194 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=195
Page 195 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=196
Page 196 of 787
        "generic_name": [
          "ANHYDROUS CITRIC ACID, ASPIRIN, AND SODIUM BICARBONATE"
        "brand_name": [
          "Alka-Seltzer Original"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=197
Page 197 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, SALICYLAMIDE"
        "brand_name": [
          "PAIN RELIEVER"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=198
Page 198 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "SohMed Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=199
Page 199 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=200
Page 200 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "7 Select Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=201
Page 201 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID), AND CAFFEINE"
        "brand_name": [
          "Excedrin Extra Strength Caplets"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=202
Page 202 of 787
        "generic_name": [
          "ASPIRIN 81 MG"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=203
Page 203 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Sunmark Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=204
Page 204 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE"
        "brand_name": [
          "Butalbital, Aspirin, Caffeine, and Codeine Phosphate"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP in controlled clinical trials, three (0.8%) discontinued treatment with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP treated patients in controlled clinical trials comparing Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Body System/ Adverse Event Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP (N = 382) Placebo (N= 377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP the adverse events were not necessarily caused by Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Adverse events are classified by body system and frequency. \"Frequent\" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. \"Infrequent\" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP that have been received since market introduction and that were not reported in clinical trials by the patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=205
Page 205 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Lil Drug Store Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=206
Page 206 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin adult low dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=207
Page 207 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE CAPSULES"
        "brand_name": [
          "Synalgos"
 
      "drug_interactions": [
        "Drug Interactions The CNS-depressant effects of Synalgos-DC may be additive with that of other CNS depressants. See " WARNINGS ." Aspirin may enhance the effects of anticoagulants and inhibit the uricosuric effects of uricosuric agents."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequently observed reactions include lightheadedness, dizziness, drowsiness, sedation, nausea, vomiting, constipation, pruritus, and skin reactions."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=208
Page 208 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspir Low"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=209
Page 209 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pain Reliever Added Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=210
Page 210 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Bayer AM extra stength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=211
Page 211 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=212
Page 212 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=213
Page 213 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "sunmark aspirin adult low strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=214
Page 214 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=215
Page 215 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=216
Page 216 of 787
        "generic_name": [
          "ACETAMINOPHEN, CAFFEINE, ASPIRIN, SALICYLAMIDE"
        "brand_name": [
          "Pain Stopper Extra"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=217
Page 217 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Plus Pharma NSAID 325 mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=218
Page 218 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, ISOPROPYL ALCOHOL, BENZOCAINE, ASPIRIN, ETHYL ALCOHOL"
        "brand_name": [
          "Good Neighbor Pharmacy Emergency Preparedness and First Aid Contains 167 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=219
Page 219 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Family Wellness Migraine Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=220
Page 220 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=221
Page 221 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=222
Page 222 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Alka-Seltzer Plus Cold and Cough Formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=223
Page 223 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Genuine Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=224
Page 224 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=225
Page 225 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=226
Page 226 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "FormuCare Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=227
Page 227 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN"
        "brand_name": [
          "ARC FIRST AID Contains 101 PIECES Hardcase"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=228
Page 228 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=229
Page 229 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=230
Page 230 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Anacin AF"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=231
Page 231 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN LOW DOSE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=232
Page 232 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=233
Page 233 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=234
Page 234 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin adult low strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=235
Page 235 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "BUFFERIN LOW DOSE BUFFERED ASPIRIN"
 
      "adverse_reactions": [
        "Allergy Alert Aspirin may cause a severe allergic reaction which may include: - hives - facial swelling - asthma (wheezing) - shock Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you: are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) have 3 or more alcoholic drinks every day while using this product take more or for a longer time than directed"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=236
Page 236 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, BENZOCAINE, ALCOHOL, IBUPROFEN, ACETAMINOPHEN, ASPIRIN, ISOPROPYL ALCOHOL"
        "brand_name": [
          "25 Person ANSI"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=237
Page 237 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=238
Page 238 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=239
Page 239 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=240
Page 240 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=241
Page 241 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Safety Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=242
Page 242 of 787
        "generic_name": [
          "ACETAMINOPHEN, CAFFEINE, ASPIRIN, SALICYLAMIDE"
        "brand_name": [
          "Pain Stoppers Regular"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=243
Page 243 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Equaline aspirin adult low dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=244
Page 244 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=245
Page 245 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN"
        "brand_name": [
          "EXCEDRIN BACK AND BODY"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=246
Page 246 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "rexall aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=247
Page 247 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOTROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "K-Mart SmartSense First Aid Contains 303 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=248
Page 248 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=249
Page 249 of 787
        "generic_name": [
          "CARISOPRODOL AND ASPIRIN"
        "brand_name": [
          "Carisoprodol and Aspirin"
 
      "drug_interactions": [
        "Drug Interactions Carisoprodol The sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended (see WARNINGS, Sedation). Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate (see CLINICAL PHARMACOLOGY). Coadministration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown. Aspirin Clinically important interactions may occur when certain drugs or alcohol are administered concomitantly with aspirin. Alcohol: Concomitant use of aspirin with >= 3 alcoholic drinks may increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions). Anticoagulants: Concomitant use of aspirin with anticoagulants (e.g., heparin, warfarin, clopidogrel) increases the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions). Additionally, aspirin can displace warfarin from protein binding sites, leading to prolongation of the international normalized ratio (INR). Antihypertensives : The concomitant administration of aspirin with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics may diminish the hypotensive effects of these anti-hypertensive products due to aspirin's inhibition of renal prostaglandins, which may lead to decreased renal blood flow and increased sodium and fluid retention. Concomitant use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide due to competition at the renal tubule for secretion. Corticosteroids: Concomitant administration of aspirin and corticosteroids may decrease salicylate plasma levels. Methotrexate: Aspirin may enhance the toxicity of methotrexate due to displacement of methotrexate from its plasma protein binding sites and/or reduction of the renal clearance of methotrexate. Nonsteroidal anti-inflammatory drugs (NSAIDs): The concurrent use of aspirin with selective and nonselective NSAIDs increases the risk of serious GI adverse reactions (see WARNINGS, Serious Gastrointestinal Adverse Reactions). Oral Hypoglycemics Agents: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. Products that effect urinary pH: Ammonium chloride and other drugs that acidify the urine can elevate plasma salicylate concentrations. In contrast, antacids, by alkalinizing the urine, may decrease plasma salicylate concentrations. Uricosuric Agents: Salicylates antagonize the uricosuric action of probenecid and sulfinpyrazone."
      "adverse_reactions": [
        "ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following adverse reactions which have occurred with the administration of the individual products alone may also occur with the use of Carisoprodol and Aspirin Tablets. The following events have been reported during post-approval individual use of carisoprodol and aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Carisoprodol The following events have been reported during post-approval use of carisoprodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular: Tachycardia, postural hypotension, and facial flushing (see OVERDOSAGE). Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures (see OVERDOSAGE). Gastrointestinal: Nausea, vomiting, and epigastric discomfort. Hematologic: Leukopenia, pancytopenia Aspirin The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including abdominal pain, anorexia, nausea, vomiting, gastritis, and occult bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions and PRECAUTIONS, Gastrointestinal Adverse Reactions ). Other adverse reactions associated with the use of aspirin include elevated liver enzymes, rash, pruritus, purpura, intracranial hemorrhage, interstitial nephritis, acute renal failure, and tinnitus. Tinnitus may be a symptom of high serum salicylate levels (see OVERDOSAGE)."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=250
Page 250 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "drug_interactions": [
        "3. Drug Interactions: Patients receiving narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with Butalbital, Aspirin, and Caffeine Tablets may exhibit additive CNS depressant effects. When combined therapy is contemplated, the dose of one or both agents should be reduced. DRUGS EFFECT Aspirin w/anti-inflammatory agents Increased ulcerogenic effects. Butalbital w/coumarin anticoagulants Decreased effect of anticoagulant because of increased metabolism resulting from enzyme induction. Butalbital w/tricyclic antidepressants Decreased blood levels of the antidepressant."
      "adverse_reactions": [
        "ADVERSE REACTIONS: The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. Mental confusion or depression can occur due to intolerance or overdosage of butalbital. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=251
Page 251 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=252
Page 252 of 787
        "generic_name": [
          "ASPIRIN ACETAMINOPHEN CAFFEINE"
        "brand_name": [
          "CITRAMON"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=253
Page 253 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=254
Page 254 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=255
Page 255 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Ascriptin Regular Strength Buffered Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=256
Page 256 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=257
Page 257 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Good Sense headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=258
Page 258 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=259
Page 259 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Pain Relief Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=260
Page 260 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Solves - aspirin Cherry"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=261
Page 261 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspir Low"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=262
Page 262 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Healthy Accents Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=263
Page 263 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=264
Page 264 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=265
Page 265 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=266
Page 266 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=267
Page 267 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=268
Page 268 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID, SODIUM BICARBONATE"
        "brand_name": [
          "Medique Medi Seltzer"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=269
Page 269 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Strength, Enteric"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=270
Page 270 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=271
Page 271 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=272
Page 272 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "sunmark aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=273
Page 273 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE"
        "brand_name": [
          "EXCEDRIN MIGRAINE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=274
Page 274 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=275
Page 275 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric coated aspirin Regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=276
Page 276 of 787
        "generic_name": [
          "ASPIRIN, ACETAMINOPHEN, CAFFEINE, SALICYLAMIDE"
        "brand_name": [
          "PAIN TERMINATOR"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=277
Page 277 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=278
Page 278 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Pharbest Aspirin 325mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=279
Page 279 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=280
Page 280 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "7 Select Migraine Formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=281
Page 281 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=282
Page 282 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=283
Page 283 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Good Neighbor Pharmacy aspirin orange flavor chewable"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=284
Page 284 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=285
Page 285 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=286
Page 286 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=287
Page 287 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID), AND CAFFEINE"
        "brand_name": [
          "Excedrin Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=288
Page 288 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=289
Page 289 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=290
Page 290 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin NSAID"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=291
Page 291 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=292
Page 292 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "EXTRA PAIN RELIEF"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=293
Page 293 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Adult Low Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=294
Page 294 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=295
Page 295 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Miniprin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=296
Page 296 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low dose enteric coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=297
Page 297 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Direct Safety Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=298
Page 298 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE"
        "brand_name": [
          "Aspirin, Caffeine, and Dihydrocodeine Bitartrate"
 
      "drug_interactions": [
        "Drug Interactions The CNS-depressant effects of Aspirin, Caffeine, and Dihydrocodeine Bitartrate Capsule, USP may be additive with that of other CNS depressants. See "WARNINGS." Aspirin may enhance the effects of anticoagulants and inhibit the uricosuric effects of uricosuric agents."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequently observed reactions include lightheadedness, dizziness, drowsiness, sedation, nausea, vomiting, constipation, pruritus, and skin reactions."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=299
Page 299 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN LOW DOSE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=300
Page 300 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=301
Page 301 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=302
Page 302 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Smart Sense Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=303
Page 303 of 787
        "generic_name": [
          "ANHYDROUS CITRIC ACID, ASPIRIN, AND SODIUM BICARBONATE"
        "brand_name": [
          "Alka-Seltzer Original"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=304
Page 304 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=305
Page 305 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of Butalbital, Aspirin, and Caffeine Capsules, USP. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=306
Page 306 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Tri-Buffered Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=307
Page 307 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=308
Page 308 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low dose chewable"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=309
Page 309 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=310
Page 310 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Safety Coated Enteric Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=311
Page 311 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=312
Page 312 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspir Low"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=313
Page 313 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=314
Page 314 of 787
        "generic_name": [
          "MICRO-COATED ASPIRIN"
        "brand_name": [
          "Micro-Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=315
Page 315 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=316
Page 316 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=317
Page 317 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Leader Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=318
Page 318 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=319
Page 319 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=320
Page 320 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=321
Page 321 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low strength adult"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=322
Page 322 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=323
Page 323 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=324
Page 324 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Pharbest Regular Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=325
Page 325 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=326
Page 326 of 787
        "generic_name": [
          "ASPIRIN AND DIPYRIDAMOLE"
        "brand_name": [
          "Aggrenox"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS No pharmacokinetic drug-drug interaction studies were conducted with AGGRENOX capsules. The following information was obtained from the literature. Co-administration with anti-coagulants or NSAIDS can increase risk of bleeding (7.4, 7.10) Decreased renal function can occur with co-administration with NSAIDS (7.10) 7.1 Adenosine Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. 7.2 Angiotensin Converting Enzyme (ACE) Inhibitors Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. 7.3 Acetazolamide Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. 7.4 Anticoagulant Therapy (heparin and warfarin) Patients on anticoagulation therapy are at increased risk for bleeding because of drug-drug interactions and effects on platelets. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. 7.5 Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. 7.6 Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. 7.7 Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. 7.8 Diuretics The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. 7.9 Methotrexate Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired. 7.10 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function. 7.11 Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. 7.12 Uricosuric Agents (probenecid and sulfinpyrazone) Salicylates antagonize the uricosuric action of uricosuric agents."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: Hypersensitivity [ see Contraindications (4.1) ]. Allergy [ see Contraindications (4.2) ]. Risk of Bleeding [ see Warnings and Precautions (5.1) ]. The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea (6) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The efficacy and safety of AGGRENOX was established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either AGGRENOX, aspirin, ER-DP, or placebo [ see Clinical Studies (14) ]; primary endpoints included stroke (fatal or nonfatal) and death from all causes. This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization. Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with AGGRENOX where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety. Table 1 Incidence of Adverse Events in ESPS2* Individual Treatment Group Body System/Preferred Term AGGRENOX ER-DP Alone ASA Alone Placebo * Reported by >=1% of patients during AGGRENOX treatment where the incidence was greater than in those treated with placebo. Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID NOS = not otherwise specified. Total Number of Patients 1650 1654 1649 1649 Total Number (%) of Patients With at Least One On-Treatment Adverse Event 1319 (80%) 1305 (79%) 1323 (80%) 1304 (79%) Central and Peripheral Nervous System Disorders Headache 647 (39%) 634 (38%) 558 (34%) 543 (33%) Convulsions 28 (2%) 15 (1%) 28 (2%) 26 (2%) Gastrointestinal System Disorders Dyspepsia 303 (18%) 288 (17%) 299 (18%) 275 (17%) Abdominal Pain 289 (18%) 255 (15%) 262 (16%) 239 (14%) Nausea 264 (16%) 254 (15%) 210 (13%) 232 (14%) Diarrhea 210 (13%) 257 (16%) 112 (7%) 161 (10%) Vomiting 138 (8%) 129 (8%) 101 ( 6%) 118 (7%) Hemorrhage Rectum 26 (2%) 22 (1%) 16 (1%) 13 (1%) Melena 31 (2%) 10 (1%) 20 (1%) 13 (1%) Hemorrhoids 16 (1%) 13 (1%) 10 (1%) 10 (1%) GI Hemorrhage 20 (1%) 5 (0%) 15 (1%) 7 (0%) Body as a Whole - General Disorders Pain 105 (6%) 88 (5%) 103 (6%) 99 (6%) Fatigue 95 (6%) 93 (6%) 97 (6%) 90 (5%) Back Pain 76 (5%) 77 (5%) 74 (4%) 65 (4%) Accidental Injury 42 (3%) 24 (1%) 51 (3%) 37 (2%) Malaise 27 (2%) 23 (1%) 26 (2%) 22 (1%) Asthenia 29 (2%) 19 (1%) 17 (1%) 18 (1%) Syncope 17 (1%) 13 (1%) 16 (1%) 8 (0%) Psychiatric Disorders Amnesia 39 (2%) 40 (2%) 57 (3%) 34 (2%) Confusion 18 (1%) 9 (1%) 22 (1%) 15 (1%) Anorexia 19 (1%) 17 (1%) 10 (1%) 15 (1%) Somnolence 20 (1%) 13 (1%) 18 (1%) 9 (1%) Musculoskeletal System Disorders Arthralgia 91 (6%) 75 (5%) 91 (6%) 76 (5%) Arthritis 34 (2%) 25 (2%) 17 (1%) 19 (1%) Arthrosis 18 (1%) 22 (1%) 13 (1%) 14 (1%) Myalgia 20 (1%) 16 (1%) 11 (1%) 11 (1%) Respiratory System Disorders Coughing 25 (2%) 18 (1%) 32 (2%) 21 (1%) Upper Respiratory Tract Infection 16 (1%) 9 (1%) 16 (1%) 14 (1%) Cardiovascular Disorders, General Cardiac Failure 26 (2%) 17 (1%) 30 (2%) 25 (2%) Platelet, Bleeding & Clotting Disorders Hemorrhage NOS 52 (3%) 24 (1%) 46 (3%) 24 (1%) Epistaxis 39 (2%) 16 (1%) 45 (3%) 25 (2%) Purpura 23 (1%) 8 (0%) 9 (1%) 7 (0%) Neoplasm Neoplasm NOS 28 (2%) 16 (1%) 23 (1%) 20 (1%) Red Blood Cell Disorders Anemia 27 (2%) 16 (1%) 19 (1%) 9 (1%) Discontinuation due to adverse events in ESPS2 was 25% for AGGRENOX, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2) Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of>=1% in the AGGRENOX Group Treatment Groups AGGRENOX ER-DP ASA Placebo Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID Total Number of Patients 1650 1654 1649 1649 Patients with at least one Adverse Event that led to treatment discontinuation 417 (25%) 419 (25%) 318 (19%) 352 (21%) Headache 165 (10%) 166 (10%) 57 (3%) 69 (4%) Dizziness 85 (5%) 97 (6%) 69 (4%) 68 (4%) Nausea 91 (6%) 95 (6%) 51 (3%) 53 (3%) Abdominal Pain 74 (4%) 64 (4%) 56 (3%) 52 (3%) Dyspepsia 59 (4%) 61 (4%) 49 (3%) 46 (3%) Vomiting 53 (3%) 52 (3%) 28 (2%) 24 (1%) Diarrhea 35 (2%) 41 (2%) 9 (<1%) 16 (<1%) Stroke 39 (2%) 48 (3%) 57 (3%) 73 (4%) Transient Ischemic Attack 35 (2%) 40 (2%) 26 (2%) 48 (3%) Angina Pectoris 23 (1%) 20 (1%) 16 (<1%) 26 (2%) Headache was most notable in the first month of treatment. Other Adverse Events Adverse reactions that occurred in less than 1% of patients treated with AGGRENOX in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below. Body as a Whole : Allergic reaction, fever Cardiovascular : Hypotension Central Nervous System : Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage Gastrointestinal : Gastritis, ulceration and perforation Hearing and Vestibular Disorders : Tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism Heart Rate and Rhythm Disorders : Tachycardia, palpitation, arrhythmia, supraventricular tachycardia Liver and Biliary System Disorders : Cholelithiasis, jaundice, hepatic function abnormal Metabolic and Nutritional Disorders : Hyperglycemia, thirst Platelet, Bleeding and Clotting Disorders : Hematoma, gingival bleeding Psychiatric Disorders : Agitation Reproductive : Uterine hemorrhage Respiratory : Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edema Special Senses Other Disorders : Taste loss Skin and Appendages Disorders : Pruritus, urticaria Urogenital : Renal insufficiency and failure, hematuria Vascular (Extracardiac) Disorders : Flushing Laboratory Changes Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm3. 6.2 Post-Marketing Experience The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to AGGRENOX. Body as a Whole : Hypothermia, chest pain Cardiovascular : Angina pectoris Central Nervous System : Cerebral edema Fluid and Electrolyte : Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia Gastrointestinal : Pancreatitis, Reye syndrome, hematemesis Hearing and Vestibular Disorders : Hearing loss Immune System Disorders : Hypersensitivity, acute anaphylaxis, laryngeal edema Liver and Biliary System Disorders : Hepatitis, hepatic failure Musculoskeletal : Rhabdomyolysis Metabolic and Nutritional Disorders : Hypoglycemia, dehydration Platelet, Bleeding and Clotting Disorders : Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia Reproductive : Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding Respiratory : Tachypnea, dyspnea Skin and Appendages Disorders : Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematoma Urogenital : Interstitial nephritis, papillary necrosis, proteinuria Vascular (Extracardiac Disorders) : Allergic vasculitis Other adverse events : anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS The risk of GI bleeding is increased, especially in patients who are heavy alcohol users, have a history of peptic ulcer, or have coagulation abnormalities due to liver disease or vitamin K deficiency (5.1) As with other antiplatelets, there is a risk of intracranial hemorrhage (5.1) Avoid use in patients with severe hepatic or renal insufficiency (5.2, 5.3) Can cause fetal harm when administered to a pregnant woman, especially in the third trimester (5.4) 5.1 Risk of Bleeding Intracranial Hemorrhage In ESPS2 the incidence of intracranial hemorrhage was 0.6% in the AGGRENOX group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups. Coagulation Abnormalities Even low doses of aspirin can inhibit platelet function leading to an increase in bleeding time. This can adversely affect patients with inherited or acquired (liver disease or vitamin K deficiency) bleeding disorders [see Drug Interactions (7.4) ]. Gastrointestinal (GI) Side Effects GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur. In ESPS2 the incidence of gastrointestinal bleeding was 4.1% in the AGGRENOX group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups. Peptic Ulcer Disease Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding. Alcohol Warning Because AGGRENOX contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. 5.2 Renal Failure Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.3 Hepatic Insufficiency Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.4 Pregnancy Because AGGRENOX contains aspirin, AGGRENOX can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid AGGRENOX in the third trimester of pregnancy [ see Use in Specific Populations (8.1) ]. Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m2 basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of AGGRENOX. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of AGGRENOX in pregnant women. If AGGRENOX is used during pregnancy, or if the patient becomes pregnant while taking AGGRENOX, inform the patient of the potential hazard to the fetus. 5.5 Coronary Artery Disease Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole. For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications. 5.6 Hypotension Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension. 5.7 General AGGRENOX capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=327
Page 327 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=328
Page 328 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=329
Page 329 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=330
Page 330 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=331
Page 331 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Topcare Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=332
Page 332 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE"
        "brand_name": [
          "Butalbital, Aspirin, Caffeine and Codeine Phosphate"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP in controlled clinical trials, three (0.8%) discontinued treatment with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP treated patients in controlled clinical trials comparing Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Butalbital, Aspirin, Caffeine, and Body System/ Codeine Phosphate Capsules, USP Placebo Adverse Event (N = 382) (N = 377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, the adverse events were not necessarily caused by Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Adverse events are classified by body system and frequency. "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. "Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, that have been received since market introduction and that were not reported in clinical trials by the patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=333
Page 333 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Signature Care Migraine Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=334
Page 334 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=335
Page 335 of 787
        "generic_name": [
          "ASPIRIN, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Alka-Seltzer Plus Day Non Drowsy Cold Medicine Citrus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=336
Page 336 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81mg Adult Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=337
Page 337 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Equaline Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=338
Page 338 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=339
Page 339 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=340
Page 340 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=341
Page 341 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID MONOHYDRATE, AND SODIUM BICARBONATE"
        "brand_name": [
          "Vida Mia Pain Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=342
Page 342 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "pain reliever extra strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=343
Page 343 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=344
Page 344 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief to Go"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=345
Page 345 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=346
Page 346 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Chewable Adult Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=347
Page 347 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, BENZOCAINE, ALCOHOL, IBUPROFEN, ACETAMINOPHEN, ASPIRIN, ISOPROPYL ALCOHOL"
        "brand_name": [
          "50 Person ANSI"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=348
Page 348 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Chewable Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=349
Page 349 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE"
        "brand_name": [
          "Back and Body Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=350
Page 350 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "care one aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=351
Page 351 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=352
Page 352 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN Low Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=353
Page 353 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=354
Page 354 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=355
Page 355 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=356
Page 356 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Zee Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=357
Page 357 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=358
Page 358 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, ISOPROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN,"
        "brand_name": [
          "GENUINE FIRST AID Emergency Preparedness Contains 167 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=359
Page 359 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Delayed Release"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=360
Page 360 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low dose enteric coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=361
Page 361 of 787
        "generic_name": [
          "ASPIRIN, ACETAMINOPHEN, CAFFEINE"
        "brand_name": [
          "PAIN TERMINATOR 2 SEVERE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=362
Page 362 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=363
Page 363 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=364
Page 364 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=365
Page 365 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=366
Page 366 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN"
        "brand_name": [
          "ARC FIRST AID Contains 101 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=367
Page 367 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Leader migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=368
Page 368 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Fasprin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=369
Page 369 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg NSAID Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=370
Page 370 of 787
        "generic_name": [
          "ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE"
        "brand_name": [
          "Alka Seltzer"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=371
Page 371 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE"
        "brand_name": [
          "Back and Body Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=372
Page 372 of 787
        "generic_name": [
          "ANHYDROUS CITRIC ACID, SODIUM BICARBONATE, AND ASPIRIN"
        "brand_name": [
          "Alka-Seltzer XTRA STRENGTH"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=373
Page 373 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "topcare headache formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=374
Page 374 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Handy Solutions GENUINE ASPIRIN BAYER"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=375
Page 375 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=376
Page 376 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=377
Page 377 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Value Pharma Aspirin Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=378
Page 378 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=379
Page 379 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN"
        "brand_name": [
          "ARC Emergency Preparedness FIRST AID Contains 202 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=380
Page 380 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Pain Relief Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=381
Page 381 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Excedrin Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=382
Page 382 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=383
Page 383 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Safety Coated Adult Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=384
Page 384 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, ISOPROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN,"
        "brand_name": [
          "ARC FIRST AID Emergency Preparedness Contains 167 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=385
Page 385 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Alka-Seltzer Plus Cold Medicine Sparkling Original"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=386
Page 386 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=387
Page 387 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE"
        "brand_name": [
          "Butalbital, Aspirin, Caffeine and Codeine Phosphate"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly ObservedThe most commonly reported adverse events associated with the use of butalbital, aspirin, caffeine, and codeine phosphate capsules and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment DiscontinuationOf the 382 patients treated with butalbital, aspirin, caffeine, and codeine phosphate capsules in controlled clinical trials, three (0.8%) discontinued treatment with butalbital, aspirin, caffeine, and codeine phosphate capsules because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical TrialsThe following table summarizes the incidence rates of the adverse events reported by at least 1% of the butalbital, aspirin, caffeine, and codeine phosphate capsules treated patients in controlled clinical trials comparing butalbital, aspirin, caffeine, and codeine phosphate capsules to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Body System/ Adverse Event Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules (N = 382) Placebo (N = 377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical TrialsThe listing that follows represents the proportion of the 382 patients exposed to butalbital, aspirin, caffeine, and codeine phosphate capsules while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving butalbital, aspirin, caffeine, and codeine phosphate capsules, the adverse events were not necessarily caused by butalbital, aspirin, caffeine, and codeine phosphate capsules. Adverse events are classified by body system and frequency. "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. "Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with butalbital, aspirin, caffeine, and codeine phosphate capsules, that have been received since market introduction and that were not reported in clinical trials by the patients treated with butalbital, aspirin, caffeine, and codeine phosphate capsules, are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: Abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=388
Page 388 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=389
Page 389 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=390
Page 390 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=391
Page 391 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "BC Cherry"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=392
Page 392 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=393
Page 393 of 787
        "generic_name": [
          "ASPIRIN, IBUPROFEN, ACETAMINOPHEN, ALCOHOL, BENZALKONIUM CHLORIDE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE"
        "brand_name": [
          "Ready America First Aid Pocket - 33 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=394
Page 394 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND DIPHENHYDRAMINE CITRATE"
        "brand_name": [
          "HEADACHE RELIEF PM"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=395
Page 395 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Chewable"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=396
Page 396 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "TopCare Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=397
Page 397 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Pharbest Aspirin 325mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=398
Page 398 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=399
Page 399 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Safety Coated Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=400
Page 400 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low dose enteric coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=401
Page 401 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Plus Pharma NSAID Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=402
Page 402 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=403
Page 403 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, BENZOCAINE, ALCOHOL, IBUPROFEN, ACETAMINOPHEN, ASPIRIN"
        "brand_name": [
          "10 Person ANSI"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=404
Page 404 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=405
Page 405 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=406
Page 406 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=407
Page 407 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=408
Page 408 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=409
Page 409 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOTROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "FIRST AID Contains 303 PIECES HARDCASE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=410
Page 410 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=411
Page 411 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE"
        "brand_name": [
          "EXCEDRIN MIGRAINE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=412
Page 412 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pain Reliever Plus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=413
Page 413 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "BAYER"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=414
Page 414 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN"
        "brand_name": [
          "Coachs First Aid Contains 102 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=415
Page 415 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=416
Page 416 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "good sense aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=417
Page 417 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bufferin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=418
Page 418 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=419
Page 419 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Topcare Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=420
Page 420 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin enteric safety coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=421
Page 421 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=422
Page 422 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "good neighbor pharmacy aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=423
Page 423 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=424
Page 424 of 787
        "generic_name": [
          "ASPIRIN, DOXYLAMINE SUCCINATE, PHENYLEPHRINE BITARTRATE, AND DEXTROMETHORPHAN HYDROBROMIDE"
        "brand_name": [
          "Alka-Seltzer Plus Night Cold Medicine"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=425
Page 425 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=426
Page 426 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=427
Page 427 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=428
Page 428 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE"
        "brand_name": [
          "Butalbital, Aspirin, Caffeine and Codeine Phosphate"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP in controlled clinical trials, three (0.8%) discontinued treatment with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP treated patients in controlled clinical trials comparing Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Butalbital, Aspirin, Caffeine, and Body System/ Codeine Phosphate Capsules, USP Placebo Adverse Event (N = 382) (N = 377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, the adverse events were not necessarily caused by Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Adverse events are classified by body system and frequency. "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. "Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, that have been received since market introduction and that were not reported in clinical trials by the patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=429
Page 429 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=430
Page 430 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=431
Page 431 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=432
Page 432 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=433
Page 433 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "coated aspirin low-dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=434
Page 434 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Anacin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=435
Page 435 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=436
Page 436 of 787
        "generic_name": [
          "ASPIRIN 325 MG"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=437
Page 437 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=438
Page 438 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Micro-Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=439
Page 439 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Leader migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=440
Page 440 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, SALICYLAMIDE AND CAFFEINE"
        "brand_name": [
          "Green Guard Pain and Ache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=441
Page 441 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=442
Page 442 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=443
Page 443 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=444
Page 444 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=445
Page 445 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pain Reliever Plus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=446
Page 446 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=447
Page 447 of 787
        "generic_name": [
          "ACETAMINOPHEN AND ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Goodys PM Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=448
Page 448 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=449
Page 449 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=450
Page 450 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Formula Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=451
Page 451 of 787
        "generic_name": [
          "ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Orphenadrine Citrate, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Side effects of Orphenadrine Citrate, Aspirin, and Caffeine Tablets are those seen with aspirin and caffeine or those usually associated with mild anticholinergic agents. These may include tachycardia, palpitation, urinary hesitancy or retention, dry mouth, blurred vision, dilation of the pupil, increased intraocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, and rarely, urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of confusion. Mild central excitation and occasional hallucinations may be observed. These mild side effects can usually be eliminated by reduction in dosage. One case of aplastic anemia associated with the use of Orphenadrine Citrate, Aspirin, and Caffeine Tablets has been reported. No causal relationship has been established. Rare G.I. hemorrhage due to aspirin content may be associated with the administration of Orphenadrine Citrate, Aspirin, and Caffeine Tablets. Some patients may experience transient episodes of lightheadedness, dizziness or syncope."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=452
Page 452 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Healthy Accents Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=453
Page 453 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspir Low"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=454
Page 454 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=455
Page 455 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Equaline headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=456
Page 456 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Buffered Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=457
Page 457 of 787
        "generic_name": [
          "ASPIRIN, SODIUM BICARBONATE, CITRIC ACID"
        "brand_name": [
          "BROMO SELTZER"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=458
Page 458 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=459
Page 459 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=460
Page 460 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Quality Choice Effervescent Cold Relief Plus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=461
Page 461 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Good Neighbor Pharmacy Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=462
Page 462 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "equate aspirin chewable"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=463
Page 463 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Childrens Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=464
Page 464 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Pain Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=465
Page 465 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of Butalbital, Aspirin, and Caffeine Capsules, USP. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=466
Page 466 of 787
        "generic_name": [
          "ASPIRIN 81 MG"
        "brand_name": [
          "Aspirin Chewable"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=467
Page 467 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=468
Page 468 of 787
        "generic_name": [
          "ASPIRIN AND DIPYRIDAMOLE"
        "brand_name": [
          "Aggrenox"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding (7.1) Decreased renal function can occur with co-administration with NSAIDs (7.1) 7.1 Drug Interaction Study Information Obtained From Literature Adenosine Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Angiotensin Converting Enzyme (ACE) Inhibitors Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. Acetazolamide Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. Anticoagulants and Antiplatelets Patients taking AGGRENOX in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. Anagrelide Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding. Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Diuretics The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Methotrexate Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function. Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. Uricosuric Agents (probenecid and sulfinpyrazone) Salicylates antagonize the uricosuric action of uricosuric agents."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: Hypersensitivity [ see Contraindications (4.1) ] Allergy [ see Contraindications (4.2) ] Risk of Bleeding [ see Warnings and Precautions (5.1) ] The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea (6) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The efficacy and safety of AGGRENOX was established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo-controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either AGGRENOX, aspirin, ER-DP, or placebo [ see Clinical Studies (14) ]; primary endpoints included stroke (fatal or nonfatal) and death from all causes. This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization. Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with AGGRENOX where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety. Table 1 Incidence of Adverse Events in ESPS2a Individual Treatment Group AGGRENOX ER-DP Alone ASA Alone Placebo Body System/Preferred Term aReported by >=1% of patients during AGGRENOX treatment where the incidence was greater than in those treated with placebo. Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID. NOS = not otherwise specified. 1650 1654 1649 1649 Total Number of Patients Total Number (%) of Patients With at Least One On-Treatment Adverse Event 1319 (80%) 1305 (79%) 1323 (80%) 1304 (79%) Central and Peripheral Nervous System Disorders Headache 647 (39%) 634 (38%) 558 (34%) 543 (33%) Convulsions 28 (2%) 15 (1%) 28 (2%) 26 (2%) Gastrointestinal System Disorders Dyspepsia 303 (18%) 288 (17%) 299 (18%) 275 (17%) Abdominal Pain 289 (18%) 255 (15%) 262 (16%) 239 (14%) Nausea 264 (16%) 254 (15%) 210 (13%) 232 (14%) Diarrhea 210 (13%) 257 (16%) 112 (7%) 161 (10%) Vomiting 138 (8%) 129 (8%) 101 (6%) 118 (7%) Hemorrhage Rectum 26 (2%) 22 (1%) 16 (1%) 13 (1%) Melena 31 (2%) 10 (1%) 20 (1%) 13 (1%) Hemorrhoids 16 (1%) 13 (1%) 10 (1%) 10 (1%) GI Hemorrhage 20 (1%) 5 (0%) 15 (1%) 7 (0%) Body as a Whole - General Disorders Pain 105 (6%) 88 (5%) 103 (6%) 99 (6%) Fatigue 95 (6%) 93 (6%) 97 (6%) 90 (5%) Back Pain 76 (5%) 77 (5%) 74 (4%) 65 (4%) Accidental Injury 42 (3%) 24 (1%) 51 (3%) 37 (2%) Malaise 27 (2%) 23 (1%) 26 (2%) 22 (1%) Asthenia 29 (2%) 19 (1%) 17 (1%) 18 (1%) Syncope 17 (1%) 13 (1%) 16 (1%) 8 (0%) Psychiatric Disorders Amnesia 39 (2%) 40 (2%) 57 (3%) 34 (2%) Confusion 18 (1%) 9 (1%) 22 (1%) 15 (1%) Anorexia 19 (1%) 17 (1%) 10 (1%) 15 (1%) Somnolence 20 (1%) 13 (1%) 18 (1%) 9 (1%) Musculoskeletal System Disorders Arthralgia 91 (6%) 75 (5%) 91 (6%) 76 (5%) Arthritis 34 (2%) 25 (2%) 17 (1%) 19 (1%) Arthrosis 18 (1%) 22 (1%) 13 (1%) 14 (1%) Myalgia 20 (1%) 16 (1%) 11 (1%) 11 (1%) Respiratory System Disorders Coughing 25 (2%) 18 (1%) 32 (2%) 21 (1%) Upper Respiratory Tract Infection 16 (1%) 9 (1%) 16 (1%) 14 (1%) Cardiovascular Disorders, General Cardiac Failure 26 (2%) 17 (1%) 30 (2%) 25 (2%) Platelet, Bleeding and Clotting Disorders Hemorrhage NOS 52 (3%) 24 (1%) 46 (3%) 24 (1%) Epistaxis 39 (2%) 16 (1%) 45 (3%) 25 (2%) Purpura 23 (1%) 8 (0%) 9 (1%) 7 (0%) Neoplasm Neoplasm NOS 28 (2%) 16 (1%) 23 (1%) 20 (1%) Red Blood Cell Disorders Anemia 27 (2%) 16 (1%) 19 (1%) 9 (1%) Discontinuation due to adverse events in ESPS2 was 25% for AGGRENOX, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2) Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of >=1% in the AGGRENOX Group Treatment Groups AGGRENOX ER-DP ASA Placebo Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID. Total Number of Patients 1650 1654 1649 1649 Patients with at least one Adverse Event that led to treatment discontinuation 417 (25%) 419 (25%) 318 (19%) 352 (21%) Headache 165 (10%) 166 (10%) 57 (3%) 69 (4%) Dizziness 85 (5%) 97 (6%) 69 (4%) 68 (4%) Nausea 91 (6%) 95 (6%) 51 (3%) 53 (3%) Abdominal Pain 74 (4%) 64 (4%) 56 (3%) 52 (3%) Dyspepsia 59 (4%) 61 (4%) 49 (3%) 46 (3%) Vomiting 53 (3%) 52 (3%) 28 (2%) 24 (1%) Diarrhea 35 (2%) 41 (2%) 9 (<1%) 16 (<1%) Stroke 39 (2%) 48 (3%) 57 (3%) 73 (4%) Transient Ischemic Attack 35 (2%) 40 (2%) 26 (2%) 48 (3%) Angina Pectoris 23 (1%) 20 (1%) 16 (<1%) 26 (2%) Headache was most notable in the first month of treatment. Other Adverse Events Adverse reactions that occurred in less than 1% of patients treated with AGGRENOX in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below. Body as a Whole: Allergic reaction, fever Cardiovascular: Hypotension Central Nervous System: Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage Gastrointestinal: Gastritis, ulceration and perforation Hearing and Vestibular Disorders: Tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism Heart Rate and Rhythm Disorders: Tachycardia, palpitation, arrhythmia, supraventricular tachycardia Liver and Biliary System Disorders: Cholelithiasis, jaundice, hepatic function abnormal Metabolic and Nutritional Disorders: Hyperglycemia, thirst Platelet, Bleeding and Clotting Disorders: Hematoma, gingival bleeding Psychiatric Disorders: Agitation Reproductive: Uterine hemorrhage Respiratory: Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edema Special Senses Other Disorders: Taste loss Skin and Appendages Disorders: Pruritus, urticaria Urogenital: Renal insufficiency and failure, hematuria Vascular (Extracardiac) Disorders: Flushing Laboratory Changes Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm3. 6.2 Post-Marketing Experience The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to AGGRENOX. Body as a Whole: Hypothermia, chest pain Cardiovascular: Angina pectoris Central Nervous System: Cerebral edema Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia Gastrointestinal: Pancreatitis, Reye syndrome, hematemesis Hearing and Vestibular Disorders: Hearing loss Immune System Disorders: Hypersensitivity, acute anaphylaxis, laryngeal edema Liver and Biliary System Disorders: Hepatitis, hepatic failure Musculoskeletal: Rhabdomyolysis Metabolic and Nutritional Disorders: Hypoglycemia, dehydration Platelet, Bleeding and Clotting Disorders: Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia Reproductive: Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding Respiratory: Tachypnea, dyspnea Skin and Appendages Disorders: Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematoma Urogenital: Interstitial nephritis, papillary necrosis, proteinuria Vascular (Extracardiac) Disorders: Allergic vasculitis Other Adverse Events: anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS AGGRENOX increases the risk of bleeding (5.1) Avoid use in patients with severe hepatic or renal insufficiency (5.2, 5.3) Can cause fetal harm when administered to a pregnant woman, especially in the third trimester (5.4) 5.1 Risk of Bleeding AGGRENOX increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin, anagrelide, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug Interactions (7.1) ]. Intracranial Hemorrhage In European Stroke Prevention Study-2 (ESPS2), the incidence of intracranial hemorrhage was 0.6% in the AGGRENOX group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups. Gastrointestinal (GI) Side Effects GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur. In ESPS2, the incidence of gastrointestinal bleeding was 4.1% in the AGGRENOX group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups. Peptic Ulcer Disease Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding. Alcohol Warning Because AGGRENOX contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. 5.2 Renal Failure Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.3 Hepatic Insufficiency Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.4 Pregnancy Because AGGRENOX contains aspirin, AGGRENOX can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid AGGRENOX in the third trimester of pregnancy [ see Use in Specific Populations (8.1) ]. Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m2 basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of AGGRENOX. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of AGGRENOX in pregnant women. If AGGRENOX is used during pregnancy, or if the patient becomes pregnant while taking AGGRENOX, inform the patient of the potential hazard to the fetus. 5.5 Coronary Artery Disease Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole. For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications. 5.6 Hypotension Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension. 5.7 General AGGRENOX capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=469
Page 469 of 787
        "generic_name": [
          "OXYCODONE AND ASPIRIN"
        "brand_name": [
          "Oxycodone and Aspirin"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Serious adverse reactions that may be associated with oxycodone and aspirin tablet use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock (see OVERDOSAGE). The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation and pruritus. Aspirin may increase the likelihood of hemorrhage due to its effect on the gastric mucosa and platelet function. Furthermore, aspirin has the potential to cause anaphylaxis in hypersensitive patients as well as angioedema especially in patients with chronic urticaria. Other adverse reactions due to aspirin use include anorexia, reversible hepatotoxicity, leukopenia, thrombocytopenia, purpura, decreased plasma iron concentration, and shortened erythrocyte survival time. Other adverse reactions obtained from postmarketing experiences with oxycodone and aspirin tablets are listed by organ system and in decreasing order of severity and/or frequency as follows: Body as a Whole allergic reaction, malaise, asthenia, headache, anaphylaxis, fever, hypothermia, thirst, increased sweating, accident, accidental overdose, non-accidental overdose. Cardiovascular tachycardia, dysrhythmias, hypotension, orthostatic hypotension, bradycardia, palpitations Central and Peripheral Nervous System stupor, paresthesia, agitation, cerebral edema, coma, confusion, dizziness, headache, subdural or intracranial hemorrhage, lethargy, seizures, anxiety, mental impairment Fluid and Electrolyte dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis Gastrointestinal hemorrhagic gastric/duodenal ulcer, gastric/peptic ulcer, dyspepsia, abdominal pain, diarrhea, eructation, dry mouth, gastrointestinal bleeding, intestinal perforation, nausea, vomiting, transient elevations of hepatic enzymes, hepatitis, Reye's syndrome, pancreatitis, intestinal obstruction, ileus Hearing and Vestibular hearing loss, tinnitus. Patients with high frequency loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism. Hematologic unspecified hemorrhage, purpura, reticulocytosis, prolongation of prothrombin time, disseminated intravascular coagulation, ecchymosis, thrombocytopenia. Hypersensitivity acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction Metabolic and Nutritional hypoglycemia, hyperglycemia, acidosis, alkalosis Musculoskeletal rhabdomyolysis Ocular miosis, visual disturbances, red eye Psychiatric drug dependence, drug abuse, somnolence, depression, nervousness, hallucination Reproductive prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding, closure of patent ductus arteriosis Respiratory System bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema Skin and Appendages urticaria, rash, flushing Urogenital interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=470
Page 470 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=471
Page 471 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=472
Page 472 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=473
Page 473 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Smart Sense Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=474
Page 474 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Good Neighbor Pharmacy Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=475
Page 475 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE"
        "brand_name": [
          "butalbital, aspirin, caffeine and codeine phosphate"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly ObservedThe most commonly reported adverse events associated with the use of ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness and dizziness. Associated with Treatment DiscontinuationOf the 382 patients treated with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) in controlled clinical trials, three (0.8%) discontinued treatment with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical TrialsThe following table summarizes the incidence rates of the adverse events reported by at least 1% of the ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) treated patients in controlled clinical trials comparing ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate, USP Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Body System/Adverse Event Butalbital, Aspirin, Caffeine, and Codeine Phosphate, USP (N=382) Placebo (N=377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical TrialsThe listing that follows represents the proportion of the 382 patients exposed to ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), the adverse events were not necessarily caused by ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP). Adverse events are classified by body system and frequency, \"Frequent\" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. \"Infrequent\" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous System: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness and sluggishness. Autonomic Nervous System: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), that have been received since market introduction and that were not reported in clinical trials by the patients treated with ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous System: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous System: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of ASCOMP(R) with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP). Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=476
Page 476 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Enteric Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=477
Page 477 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=478
Page 478 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=479
Page 479 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=480
Page 480 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN"
        "brand_name": [
          "FIRST AID Contains 101 PIECES HARDCASE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=481
Page 481 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Care One headache relief added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=482
Page 482 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of Butalbital, Aspirin, and Caffeine Capsules, USP. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=483
Page 483 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=484
Page 484 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low dose chewable"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=485
Page 485 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=486
Page 486 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=487
Page 487 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=488
Page 488 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=489
Page 489 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin adult low strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=490
Page 490 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Uricalm Intensive"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=491
Page 491 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Fast Release"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=492
Page 492 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=493
Page 493 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=494
Page 494 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin low dose enteric coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=495
Page 495 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=496
Page 496 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Effervescent Cold Relief"
 
      "adverse_reactions": [
        "Adverse Event Reporting: Serious side effects associated with the use of this product can be reported to the following address or by calling the following telephone number."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=497
Page 497 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID MONOHYDRATE, AND SODIUM BICARBONATE"
        "brand_name": [
          "Effervescent Pain Relief Fast Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=498
Page 498 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "7 Select Adult Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=499
Page 499 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=500
Page 500 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=501
Page 501 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=502
Page 502 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=503
Page 503 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "health mart migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=504
Page 504 of 787
        "generic_name": [
          "CARISOPRODOL AND ASPIRIN"
        "brand_name": [
          "CARISOPRODOL and ASPIRIN"
 
      "drug_interactions": [
        "Drug Interactions Carisoprodol: The sedative effect of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended (see WARNINGS, Sedation ). Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate (see CLINICAL PHARMACOLOGY ). Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed an induction effect of CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of carisoprodol is unknown. Aspirin: Clinically important interactions may occur when certain drugs or alcohol are administered concomitantly with aspirin. Alcohol: Concomitant use of aspirin with >= 3 alcoholic drinks may increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Anticoagulants: Concomitant use of aspirin and anticoagulants (e.g., heparin, warfarin, clopidogrel) increase the risk of GI bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Additionally, aspirin can displace warfarin from protein binding sites, leading to prolongation of the international normalized ratio (INR). Antihypertensives: The concomitant administration of aspirin with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics may diminish the hypotensive effects of these anti-hypertensive products due to aspirin's inhibition of renal prostaglandins, which may lead to decreased renal blood flow and increased sodium and fluid retention. Concomitant use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide due to competition at the renal tubule for secretion. Corticosteroids: Concomitant administration of aspirin and corticosteroids may decrease salicylate plasma levels. Methotrexate: Aspirin may enhance the toxicity of methotrexate due to displacement of methotrexate from its plasma protein binding sites and/or reduction of the renal clearance of methotrexate. Nonsteroidal anti-inflammatory drugs (NSAIDs): The concurrent use of aspirin with selective and nonselective NSAIDs increases the risk of serious GI adverse reactions (see WARNINGS, Serious Gastrointestinal Adverse Reactions ). Oral Hypoglycemics Agents: Aspirin may increase the serum glucose lowering action of insulin and sulfonylureas leading to hypoglycemia. Products that effect urinary pH: Ammonium chloride and other drugs that acidify the urine can elevate plasma salicylate concentrations. In contrast, antacids, by alkalinizing the urine, may decrease plasma salicylate concentrations. Uricosuric Agents: Salicylates antagonize the uricosuric action of probenecid and sulfinpyrazone."
      "adverse_reactions": [
        "ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals at 1-201-961-9000 or FDA at 1-800-FDA-1088 or www. fda.gov/medwatch. The following adverse reactions which have occurred with the administration of the individual products alone may also occur with the use of carisoprodol and Aspirin tablets. The following events have been reported during post-approval individual use of carisoprodol and aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Carisoprodol: The following events have been reported during post-approval use of carisoprodol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular: Tachycardia, postural hypotension, and facial flushing (see OVERDOSAGE ). Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures (see OVERDOSAGE ). Gastrointestinal: Nausea, vomiting, and epigastric discomfort. Hematologic: Leukopenia, pancytopenia. Aspirin: The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including abdominal pain, anorexia, nausea, vomiting, gastritis, and occult bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions and PRECAUTIONS, Gastrointestinal Adverse Reactions ). Other adverse reactions associated with the use of aspirin include elevated liver enzymes, rash, pruritus, purpura, intracranial hemorrhage, interstitial nephritis, acute renal failure, and tinnitus. Tinnitus may be a symptom of high serum salicylate levels (see OVERDOSAGE )."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=505
Page 505 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=506
Page 506 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=507
Page 507 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=508
Page 508 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN, BENZOCAINE, ALCOHOL"
        "brand_name": [
          "GOOD NEIGHBOR PHARMACY FIRST AID Contains 202 PIECES"
 
      "warnings_and_cautions": [
        "Warnings: For external use only. Avoid contact with eyes. If this happens, rinse thoroughly with water."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=509
Page 509 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=510
Page 510 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Equate Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=511
Page 511 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "good sense aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=512
Page 512 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspi-Cor"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=513
Page 513 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE, SALICYLAMIDE"
        "brand_name": [
          "EXAPRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=514
Page 514 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Fiorinal"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Fiorinal may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Fiorinal exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Fiorinal may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of Fiorinal. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=515
Page 515 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=516
Page 516 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=517
Page 517 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Bayer Migraine Formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=518
Page 518 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=519
Page 519 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=520
Page 520 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "health mart migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=521
Page 521 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=522
Page 522 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, ASPIRIN"
        "brand_name": [
          "K-Mart SmartSense First Aid Contains 101 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=523
Page 523 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=524
Page 524 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=525
Page 525 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=526
Page 526 of 787
        "generic_name": [
          "ASPIRIN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Alka-Seltzer Plus Night Cold Formula (Lemon)"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=527
Page 527 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=528
Page 528 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Critical Care Aspirin to Go"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=529
Page 529 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "headache relief added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=530
Page 530 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=531
Page 531 of 787
        "generic_name": [
          "ASPIRIN, ACETAMINOPHEN, IBUPROFEN, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B, BENZALKONIUM CHLORIDE, LIDOCAINE, BENZALKONIUM CHLORIDE"
        "brand_name": [
          "Genuine First Aid Industrial First Aid"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=532
Page 532 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=533
Page 533 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "good neighbor pharmacy headache relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=534
Page 534 of 787
        "generic_name": [
          "OXYCODONE AND ASPIRIN"
        "brand_name": [
          "Oxycodone and Aspirin"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Serious adverse reactions that may be associated with oxycodone and aspirin tablet use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock (see OVERDOSAGE ). The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation and pruritus. Aspirin may increase the likelihood of hemorrhage due to its effect on the gastric mucosa and platelet function. Furthermore, aspirin has the potential to cause anaphylaxis in hypersensitive patients as well as angioedema especially in patients with chronic urticaria. Other adverse reactions due to aspirin use include anorexia, reversible hepatotoxicity, leukopenia, thrombocytopenia, purpura, decreased plasma iron concentration, and shortened erythrocyte survival time. Other adverse reactions obtained from postmarketing experiences with oxycodone and aspirin tablets are listed by organ system and in decreasing order of severity and/or frequency as follows: Body as a Whole allergic reaction, malaise, asthenia, headache, anaphylaxis, fever, hypothermia, thirst, increased sweating, accident, accidental overdose, non-accidental overdose. Cardiovascular tachycardia, dysrhythmias, hypotension, orthostatic hypotension, bradycardia, palpitations Central and Peripheral Nervous System stupor, paresthesia, agitation, cerebral edema, coma, confusion, dizziness, headache, subdural or intracranial hemorrhage, lethargy, seizures, anxiety, mental impairment Fluid and Electrolyte dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis Gastrointestinal hemorrhagic gastric/duodenal ulcer, gastric/peptic ulcer, dyspepsia, abdominal pain, diarrhea, eructation, dry mouth, gastrointestinal bleeding, intestinal perforation, nausea, vomiting, transient elevations of hepatic enzymes, hepatitis, Reye syndrome, pancreatitis, intestinal obstruction, ileus Hearing and Vestibular hearing loss, tinnitus. Patients with high frequency loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism. Hematologic unspecified hemorrhage, purpura, reticulocytosis, prolongation of prothrombin time, disseminated intravascular coagulation, ecchymosis, thrombocytopenia. Hypersensitivity acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction Metabolic and Nutritional hypoglycemia, hyperglycemia, acidosis, alkalosis Musculoskeletal rhabdomyolysis Ocular miosis, visual disturbances, red eye Psychiatric drug dependence, drug abuse, somnolence, depression, nervousness, hallucination Reproductive prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding, closure of patent ductus arteriosis Respiratory System bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema Skin and Appendages urticaria, rash, flushing Urogenital interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=535
Page 535 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=536
Page 536 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=537
Page 537 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID), AND CAFFEINE"
        "brand_name": [
          "Excedrin Extra Strength Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=538
Page 538 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Sunmark Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=539
Page 539 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=540
Page 540 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Alka-Seltzer Plus Cold Formula (Orange Zest)"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=541
Page 541 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Asprin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=542
Page 542 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=543
Page 543 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=544
Page 544 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=545
Page 545 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID MONOHYDRATE, AND SODIUM BICARBONATE"
        "brand_name": [
          "Premier Value Antacid and Pain Relief Medicine"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=546
Page 546 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pain Reliever Plus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=547
Page 547 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=548
Page 548 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Good Sense Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=549
Page 549 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Chewable Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=550
Page 550 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine capsules. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=551
Page 551 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=552
Page 552 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Smart Sense migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=553
Page 553 of 787
        "generic_name": [
          "ASPIRIN, SODIUM BICARBONATE, CITRIC ACID"
        "brand_name": [
          "Effervescent Antacid and Pain Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=554
Page 554 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, ISOPROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "GENUINE FIRST AID Emergency Preparedness Contains 167 PIECES HARDCASE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=555
Page 555 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=556
Page 556 of 787
        "generic_name": [
          "CARISOPRODOL AND ASPIRIN"
        "brand_name": [
          "Carisoprodol and Aspirin"
 
      "drug_interactions": [
        "Drug Interactions Clinically important interactions may occur when certain drugs are administered concomitantly with aspirin or aspirin-containing drugs. 1. Oral Anticoagulants-By interfering with platelet function or decreasing plasma prothrombin concentration, aspirin enhances the potential for bleeding in patients on anticoagulants. 2. Methotrexate-aspirin enhances the toxic effects of this drug. 3. Probenecid and Sulfinpyrazone-large doses of aspirin reduce the uricosuric effect of both drugs. Renal excretion of salicylate may also be reduced. 4. Oral Antidiabetic Drugs-enhancement of hypoglycemia may occur. 5. Antacids-to the extent that they raise urinary pH, antacids may substantially decrease plasma salicylate concentrations; conversely, their withdrawal can result in a substantial increase. 6. Ammonium Chloride-this and other drugs that acidify a relatively alkaline urine can elevate plasma salicylate concentrations. 7. Ethyl Alcohol-enhanced aspirin-induced fecal blood loss has been reported. 8. Corticosteroids-salicylate plasma levels may be decreased when adrenal corticosteroids are given, and may be increased substantially when they are discontinued."
      "adverse_reactions": [
        "ADVERSE REACTIONS If severe reactions occur, discontinue Carisoprodol and Aspirin Tablets and initiate appropriate symptomatic and supportive therapy. The following side effects which have occurred with the administration of the individual ingredients alone may also occur with the combination. Carisoprodol: Central Nervous System: Drowsiness is the most frequent complaint and along with other CNS effects may require dosage reduction. Observed less frequently are dizziness, vertigo and ataxia. Tremor, agitation, irritability, headache, depressive reactions, syncope and insomnia have been infrequent or rare. Idiosyncratic: Idiosyncratic reactions are very rare. They are usually seen within the period of the first to fourth dose in patients having had no previous contact with the drug (see WARNINGS). Allergic: Skin rash erythema multiforme, pruritus, eosinophilia and fixed drug eruptions with cross-reaction to meprobamate have been reported. If allergic reactions occur, discontinue Carisoprodol and Aspirin Tablets and treat symptomatically. In evaluating possible allergic reactions, also consider allergy to excipients. Cardiovascular: Tachycardia, postural hypotension and facial flushing. Gastrointestinal: Nausea, vomiting, epigastric distress and hiccup. Hematologic: No serious blood dyscrasias have been attributed to carisoprodol alone. Leukopenia and pancytopenia have been reported, very rarely, in situations in which other drugs or viral infections may have been responsible. Aspirin: The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including nausea, vomiting, gastritis, occult bleeding, constipation and diarrhea. Gastric erosion, angioedema, asthma rash, pruritus and urticaria have been reported less commonly. Tinnitus is a sign of high serum salicylate levels (see OVERDOSAGE). Aspirin Intolerance: Allergic type reactions in aspirin-sensitive individuals may involve the respiratory tract or the skin. Symptoms of the former range from rhinorrhea and shortness of breath to severe asthma, and the latter may consist of urticaria, edema, rash or angioedema (giant hives). These may occur independently or in combination."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=557
Page 557 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Up and Up Migraine Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=558
Page 558 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE"
        "brand_name": [
          "Fiorinal with Codeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Fiorinal with Codeine may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Fiorinal with Codeine exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Fiorinal with Codeine may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of Fiorinal with Codeine and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with Fiorinal with Codeine in controlled clinical trials, three (0.8%) discontinued treatment with Fiorinal with Codeine because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the Fiorinal with Codeine treated patients in controlled clinical trials comparing Fiorinal with Codeine to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Fiorinal with Codeine Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Body System/ Adverse Event Fiorinal with Codeine (N = 382) Placebo (N = 377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to Fiorinal with Codeine while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving Fiorinal with Codeine, the adverse events were not necessarily caused by Fiorinal with Codeine. Adverse events are classified by body system and frequency. "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. "Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with Fiorinal with Codeine, that have been received since market introduction and that were not reported in clinical trials by the patients treated with Fiorinal with Codeine, are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of Fiorinal with Codeine. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=559
Page 559 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE"
        "brand_name": [
          "Butalbital, Aspirin, Caffeine and Codeine Phosphate"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP in controlled clinical trials, three (0.8%) discontinued treatment with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP treated patients in controlled clinical trials comparing Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP Treated Patients During Placebo Controlled Clinical Trials Incidence Rate of Adverse Events Butalbital, Aspirin, Caffeine, and Body System/ Codeine Phosphate Capsules, USP Placebo Adverse Event (N = 382) (N = 377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, the adverse events were not necessarily caused by Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Adverse events are classified by body system and frequency. "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. "Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, that have been received since market introduction and that were not reported in clinical trials by the patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=560
Page 560 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Bayer Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=561
Page 561 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "St. Joseph Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=562
Page 562 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=563
Page 563 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "headache relief added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=564
Page 564 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "safety coated aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=565
Page 565 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "health mart aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=566
Page 566 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Safety-Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=567
Page 567 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=568
Page 568 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=569
Page 569 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, BENZALKONIUM CHLORIDE, WATER, ISOPROPYL ALCOHOL, ASPIRIN, BACITRACIN ZINC,NEOMYCIN SULFATE,POLYMYXIN B SULFATE"
        "brand_name": [
          "BLUE ACME SLEEVE FIRST AID Contains 1000 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=570
Page 570 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "BackAid Inflammatory Pain Formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=571
Page 571 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=572
Page 572 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN (NSAID) AND DIPHENHYDRAMINE CITRATE"
        "brand_name": [
          "Excedrin PM Triple Action Caplets"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=573
Page 573 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=574
Page 574 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=575
Page 575 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Kroger Value Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=576
Page 576 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=577
Page 577 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID MONOHYDRATE, AND SODIUM BICARBONATE"
        "brand_name": [
          "Zee-Seltzer Antacid and Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=578
Page 578 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adults Low Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=579
Page 579 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=580
Page 580 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Value PharmaPain Reliever Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=581
Page 581 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=582
Page 582 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Advanced Aspirin Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=583
Page 583 of 787
        "generic_name": [
          "OXYCODONE HYDROCHLORIDE AND ASPIRIN"
        "brand_name": [
          "Oxycodone Hydrochloride and Aspirin"
 
      "drug_interactions": [
        "Drug/Drug Interactions with Oxycodone CYP3A4 Inhibitors and CYP450 Inducers Oxycodone is extensively metabolized by multiple metabolic pathways. CYP3A4 is the major enzyme involved in noroxycodone formation followed by CYP2B6, CYP2C9/19 and CYP2D6. Drugs that inhibit CYP3A4 activity, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations and prolonged opioid effects. Similarly, CYP450 inducers, such as rifampin, carbamazepine, and phenytoin, may induce the metabolism of oxycodone and, therefore, may cause increased clearance of the drug which could lead to a decrease in oxycodone plasma concentrations, lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. If co-administration with oxycodone and aspirin tablets is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors or CYP450 inducers. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved. Skeletal Muscle Relaxants Opioid analgesics may enhance the neuromuscular-blocking action of skeletal muscle relaxants and produce an increase in the degree of respiratory depression. CNS Depressants Patients receiving CNS depressants such as other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, centrally-acting anti-emetics, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone and aspirin tablets may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Analgesics Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, naltrexone, and butorphanol) should be administered with caution to a patient who has received or is receiving a pure opioid agonist such as oxycodone. These agonist/antagonist analgesics may reduce the analgesic effect of oxycodone or may precipitate withdrawal symptoms.",
      "adverse_reactions": [
        "ADVERSE REACTIONS Serious adverse reactions that may be associated with oxycodone and aspirin tablet use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock (see OVERDOSAGE). The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation and pruritus. Aspirin may increase the likelihood of hemorrhage due to its effect on the gastric mucosa and platelet function. Furthermore, aspirin has the potential to cause anaphylaxis in hypersensitive patients as well as angioedema especially in patients with chronic urticaria. Other adverse reactions due to aspirin use include anorexia, reversible hepatotoxicity, leukopenia, thrombocytopenia, purpura, decreased plasma iron concentration, and shortened erythrocyte survival time. Other adverse reactions obtained from post-marketing experiences with oxycodone and aspirin tablets are listed by organ system and in decreasing order of severity and/or frequency as follows: Body as a Whole: allergic reaction, malaise, asthenia, headache, anaphylaxis, fever, hypothermia, thirst, increased sweating, accident, accidental overdose, non-accidental overdose Cardiovascular: tachycardia, dysrhythmias, hypotension, orthostatic hypotension, bradycardia, palpitations Central and Peripheral Nervous System: stupor, paresthesia, agitation, cerebral edema, coma, confusion, dizziness, headache, subdural or intracranial hemorrhage, lethargy, seizures, anxiety, mental impairment Fluid and Electrolyte: dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis Gastrointestinal: hemorrhagic gastric/duodenal ulcer, gastric/peptic ulcer, dyspepsia, abdominal pain, diarrhea, eructation, dry mouth, gastrointestinal bleeding, intestinal perforation, nausea, vomiting, transient elevations of hepatic enzymes, hepatitis, Reye syndrome, pancreatitis, intestinal obstruction, ileus Hearing and Vestibular: hearing loss, tinnitus. Patients with high frequency loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism. Hematologic: unspecified hemorrhage, purpura, reticulocytosis, prolongation of prothrombin time, disseminated intravascular coagulation, ecchymosis, thrombocytopenia Hypersensitivity: acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction Metabolic and Nutritional: hypoglycemia, hyperglycemia, acidosis, alkalosis Musculoskeletal: rhabdomyolysis Ocular: miosis, visual disturbances, red eye Psychiatric: drug dependence, drug abuse, somnolence, depression, nervousness, hallucination Reproductive: prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding, closure of patent ductus arteriosis Respiratory System: bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema Skin and Appendages: urticaria, rash, flushing Urogenital: interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention"
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=584
Page 584 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=585
Page 585 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Back and Body"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=586
Page 586 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported. To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001, or the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=587
Page 587 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=588
Page 588 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=589
Page 589 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, aspirin, and caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, aspirin, and caffeine capsules may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of butalbital, aspirin, and caffeine capsules exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, aspirin, and caffeine capsules may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine capsules. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=590
Page 590 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=591
Page 591 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Up and Up aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=592
Page 592 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Ache and Pain Relief to Go"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=593
Page 593 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=594
Page 594 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=595
Page 595 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=596
Page 596 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=597
Page 597 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Pain Relief Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=598
Page 598 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "EXCEDRIN MIGRAINE"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=599
Page 599 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Topcare Migraine Formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=600
Page 600 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Up and Up Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=601
Page 601 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Care One migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=602
Page 602 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "care one aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=603
Page 603 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported. To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001, or the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=604
Page 604 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Added Strength Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=605
Page 605 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "smart sense chewable aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=606
Page 606 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=607
Page 607 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=608
Page 608 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=609
Page 609 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Arthriten Inflammatory Pain Formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=610
Page 610 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Enteric coated aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=611
Page 611 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: 1.Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. 2.Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 3.6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. 4.Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. 5.Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of Butalbital, Aspirin, and Caffeine Capsules, USP. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=612
Page 612 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=613
Page 613 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Chewable Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=614
Page 614 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Topcare Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=615
Page 615 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=616
Page 616 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=617
Page 617 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=618
Page 618 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=619
Page 619 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=620
Page 620 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Migraine Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=621
Page 621 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "BC Cherry"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=622
Page 622 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Rapid Comfort Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=623
Page 623 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=624
Page 624 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine capsules. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=625
Page 625 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Health Mart Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=626
Page 626 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "sunmark headache relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=627
Page 627 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pain Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=628
Page 628 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Adult Low Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=629
Page 629 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "good neighbor pharmacy aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=630
Page 630 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=631
Page 631 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=632
Page 632 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Ascriptin Maximum Strength Buffered Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=633
Page 633 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, CAFEINE, AND CODEINE PHOSPHATE"
        "brand_name": [
          "Ascomp with Codeine"
 
      "drug_interactions": [
        "Drug interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Ascomp with Codeine may enhance the effects of: -Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. -Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Ascomp with Codeine exceeds maximum recommended daily dosage. -6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. -Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. -Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Ascomp with Codeine may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS Commonly Observed The most commonly reported adverse events associated with the use of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness, and dizziness. Associated with Treatment Discontinuation Of the 382 patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP in controlled clinical trials, three (0.8%) discontinued treatment with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling. Incidence in Controlled Clinical Trials The following table summarizes the incidence rates of the adverse events reported by at least 1% of the Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP treated patients in controlled clinical trials comparing Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Adverse Events Reported by at Least 1% of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP Treated Patients During Placebo Controlled Clinical Trial <b>Incidence Rate of Adverse Events</b> <p> Body System/ </p> Adverse Event <p>Butalbital,</p> <p>Aspirin, Caffeine, and Codeine Phosphate Capsules, USP </p> (N = 382) <p>Placebo</p> (N = 377) Central Nervous Drowsiness 2.4% 0.5% Dizziness/Lightheadedness 2.6% 0.5% Intoxicated Feeling 1.0% 0% Gastrointestinal Nausea/Abdominal Pain 3.7% 0.8% Other Adverse Events Reported During Controlled Clinical Trials The listing that follows represents the proportion of the 382 patients exposed to Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, the adverse events were not necessarily caused by Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Adverse events are classified by body system and frequency. "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent. "Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent. Central Nervous: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, and sluggishness. Autonomic Nervous: dry mouth and hyperhidrosis. Gastrointestinal: vomiting, difficulty swallowing, and heartburn. Cardiovascular: tachycardia. Musculoskeletal: leg pain and muscle fatigue. Genitourinary: diuresis. Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus. Voluntary reports of adverse drug events, temporally associated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, that have been received since market introduction and that were not reported in clinical trials by the patients treated with Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP, are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system. Central Nervous: Abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo. Autonomic Nervous: epistaxis, flushing, miosis, salivation. Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer. Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope. Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis. Urinary: kidney impairment, urinary difficulty. Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema. The following adverse drug events may be borne in mind as potential effects of the components of Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP. Potential effects of high dosage are listed in the OVERDOSAGE section of this insert. Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis. Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia. Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=634
Page 634 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "up and up aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=635
Page 635 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "MEDIQUE Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=636
Page 636 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Stanback"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=637
Page 637 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported. To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001, or the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=638
Page 638 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Alka-Seltzer Plus"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=639
Page 639 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Formu Care pain reliever added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=640
Page 640 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=641
Page 641 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Strength Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=642
Page 642 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=643
Page 643 of 787
        "generic_name": [
          "ASPIRIN, CITRIC ACID MONOHYDRATE, AND SODIUM BICARBONATE"
        "brand_name": [
          "Pain Relief Fast Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=644
Page 644 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Value PharmaPain Reliever Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=645
Page 645 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "berkley and jensen migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=646
Page 646 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=647
Page 647 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=648
Page 648 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Pain Relief Added Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=649
Page 649 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=650
Page 650 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=651
Page 651 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=652
Page 652 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, BENZOCAINE, ALCOHOL, IBUPROFEN, ACETAMINOPHEN, ASPIRIN"
        "brand_name": [
          "Auto 157"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=653
Page 653 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "DG Health migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=654
Page 654 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Leader Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=655
Page 655 of 787
        "generic_name": [
          "ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Back and Body"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=656
Page 656 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Pain Aid ESF"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=657
Page 657 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "St. Joseph Safety Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=658
Page 658 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=659
Page 659 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Flanax Aspirin Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=660
Page 660 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "WinCo Foods Effervescent Cold Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=661
Page 661 of 787
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=662
Page 662 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=663
Page 663 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Healthy Accents headache relief added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=664
Page 664 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=665
Page 665 of 787
        "generic_name": [
          "ACETAMINOPHEN,ASPIRIN,CAFFEINE"
        "brand_name": [
          "Pain Relief Maximum Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=666
Page 666 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Sunmark migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=667
Page 667 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=668
Page 668 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Childrens Chewable Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=669
Page 669 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Goodys Migraine Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=670
Page 670 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, ISOPROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "FIRST AID Contains 303 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=671
Page 671 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Bayer Genuine Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=672
Page 672 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=673
Page 673 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "up and up chewable aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=674
Page 674 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=675
Page 675 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=676
Page 676 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Pain Reliever Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=677
Page 677 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Good Neighbor Pharmacy Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=678
Page 678 of 787
        "generic_name": [
          "ASPIRIN AND DIPYRIDAMOLE"
        "brand_name": [
          "Aspirin and Dipyridamole"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS -Co-administration with anticoagulants, antiplatelets, or NSAIDS can increase risk of bleeding (7.1) -Decreased renal function can occur with co-administration with NSAIDS (7.1) 7.1 Drug Interaction Study Information Obtained From Literature Adenosine Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Angiotensin Converting Enzyme (ACE) Inhibitors Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. Acetazolamide Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. Anticoagulants and Antiplatelets Patients taking aspirin and extended-release dipyridamole capsules in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Diuretics The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Methotrexate Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function. Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. Uricosuric Agents (probenecid and sulfinpyrazone) Salicylates antagonize the uricosuric action of uricosuric agents."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: -Hypersensitivity [see Contraindications (4.1)]. -Allergy [see Contraindications (4.2)]. -Risk of Bleeding [see Warnings and Precautions (5.1)]. -The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea (6) To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537, or drug.safety@tevapharm.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The efficacy and safety of aspirin and extended-release dipyridamole capsules were established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either aspirin and extended-release dipyridamole capsules, aspirin, ER-DP, or placebo [see Clinical Studies (14)]; primary endpoints included stroke (fatal or nonfatal) and death from all causes. This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of aspirin and extended-release dipyridamole capsules with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization. Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with aspirin and extended-release dipyridamole capsules where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety. Table 1 Incidence of Adverse Events in ESPS2Reported by >=1% of patients during aspirin and dipyridamole extended-release capsuletreatment where the incidence was greater than in those treated with placebo. Individual Treatment Group Body System/Preferred Term Aspirin and Extended-Release Dipyridamole Capsules ER-DP Alone ASA Alone Placebo Total Number of Patients 1650 1654 1649 1649 Total Number (%) of Patients With at Least One On-Treatment Adverse Event 1319 (80%) 1305 (79%) 1323 (80%) 1304 (79%) Central and Peripheral Nervous System Disorders Headache 647 (39%) 634 (38%) Convulsions 28 (2%) 15 (1%) Gastrointestinal System Disorders Dyspepsia 303 (18%) 288 (17%) Abdominal Pain 289 (18%) 255 (15%) Nausea 264 (16%) 254 (15%) Diarrhea 210 (13%) 257 (16%) Vomiting 138 (8%) 129 (8%) Hemorrhage Rectum 26 (2%) 22 (1%) Melena 31 (2%) 10 (1%) Hemorrhoids 16 (1%) 13 (1%) GI Hemorrhage 20 (1%) 5 (0%) Body as a Whole - General Disorders Pain 105 (6%) 88 (5%) Fatigue 95 (6%) 93 (6%) Back Pain 76 (5%) 77 (5%) Accidental Injury 42 (3%) 24 (1%) Malaise 27 (2%) 23 (1%) Asthenia 29 (2%) 19 (1%) Syncope 17 (1%) 13 (1%) Psychiatric Disorders Amnesia 39 (2%) 40 (2%) Confusion 18 (1%) 9 (1%) Anorexia 19 (1%) 17 (1%) Somnolence 20 (1%) 13 (1%) Musculoskeletal System Disorders Arthralgia 91 (6%) 75 (5%) Arthritis 34 (2%) 25 (2%) Arthrosis 18 (1%) 22 (1%) Myalgia 20 (1%) 16 (1%) Respiratory System Disorders Coughing 25 (2%) 18 (1%) Upper Respiratory Tract Infection 16 (1%) 9 (1%) Cardiovascular Disorders, General Cardiac Failure 26 (2%) 17 (1%) Platelet, Bleeding and Clotting Disorders Hemorrhage NOS 52 (3%) 24 (1%) Epistaxis 39 (2%) 16 (1%) Purpura 23 (1%) 8 (0%) Neoplasm Neoplasm NOS 28 (2%) 16 (1%) Red Blood Cell Disorders Anemia 27 (2%) 16 (1%) Discontinuation due to adverse events in ESPS2 was 25% for aspirin and extended-release dipyridamole capsules, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2) Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of >=1% in the aspirin and dipyridamole extended-release capsule Group Treatment Groups Aspirin and Extended-Release Dipyridamole Capsules ER-DP ASA Placebo Total Number of Patients 1650 1654 1649 1649 Patients with at least one Adverse Event that led to treatment discontinuation 417 (25%) 419 (25%) 318 (19%) 352 (21%) Headache 165 (10%) 166 (10%) 57 (3%) 69 (4%) Dizziness 85 (5%) 97 (6%) 69 (4%) 68 (4%) Nausea 91 (6%) 95 (6%) 51 (3%) 53 (3%) Abdominal Pain 74 (4%) 64 (4%) 56 (3%) 52 (3%) Dyspepsia 59 (4%) 61 (4%) 49 (3%) 46 (3%) Vomiting 53 (3%) 52 (3%) 28 (2%) 24 (1%) Diarrhea 35 (2%) 41 (2%) 9 (<1%) 16 (<1%) Stroke 39 (2%) 48 (3%) 57 (3%) 73 (4%) Transient Ischemic Attack 35 (2%) 40 (2%) 26 (2%) 48 (3%) Angina Pectoris 23 (1%) 20 (1%) 16 (<1%) 26 (2%) Headache was most notable in the first month of treatment. Other Adverse Events Adverse reactions that occurred in less than 1% of patients treated with aspirin and extended-release dipyridamole capsules in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below. Body as a Whole: Allergic reaction, fever Cardiovascular: Hypotension Central Nervous System: Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage Gastrointestinal:Gastritis, ulceration and perforation Hearing and Vestibular Disorders: Tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism Heart Rate and Rhythm Disorders: Tachycardia, palpitation, arrhythmia, supraventricular tachycardia Liver and Biliary System Disorders: Cholelithiasis, jaundice, hepatic function abnormal Metabolic and Nutritional Disorders: Hyperglycemia, thirst Platelet, Bleeding and Clotting Disorders: Hematoma, gingival bleeding Psychiatric Disorders: Agitation Reproductive: Uterine hemorrhage Respiratory: Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edema Special Senses Other Disorders: Taste loss Skin and Appendages Disorders: Pruritus, urticaria Urogenital: Renal insufficiency and failure, hematuria Vascular (Extracardiac) Disorders: Flushing Laboratory Changes Over the course of the 24-month study (ESPS2), patients treated with aspirin and extended-release dipyridamole capsules showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm3. 6.2 Post-Marketing Experience The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to aspirin and extended-release dipyridamole capsules. Body as a Whole: Hypothermia, chest pain Cardiovascular: Angina pectoris Central Nervous System: Cerebral edema Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia Gastrointestinal: Pancreatitis, Reye syndrome, hematemesis Hearing and Vestibular Disorders: Hearing loss Immune System Disorders: Hypersensitivity, acute anaphylaxis, laryngeal edema Liver and Biliary System Disorders: Hepatitis, hepatic failure Musculoskeletal: Rhabdomyolysis Metabolic and Nutritional Disorders: Hypoglycemia, dehydration Platelet, Bleeding and Clotting Disorders: Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia Reproductive: Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding Respiratory: Tachypnea, dyspnea Skin and Appendages Disorders: Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematoma Urogenital: Interstitial nephritis, papillary necrosis, proteinuria Vascular (Extracardiac Disorders): Allergic vasculitis Other Adverse Events: anorexia,aplastic anemia, migraine, pancytopenia, thrombocytosis."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS -Aspirin and extended-release dipyridamole capsules increase the risk of bleeding (5.1) -Avoid use in patients with severe hepatic or renal insufficiency (5.2, 5.3) -Can cause fetal harm when administered to a pregnant woman, especially in the third trimester (5.4) 5.1 Risk of Bleeding Aspirin and extended-release dipyridamole capsules increase the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug Interactions ( 7.1 ) ]. Intracranial Hemorrhage In ESPS2 the incidence of intracranial hemorrhage was 0.6% in the aspirin and dipyridamole extended-release capsule group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups. Gastrointestinal (GI) Side Effects GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur. In ESPS2 the incidence of gastrointestinal bleeding was 4.1% in the aspirin and dipyridamole extended-release capsule group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups. Peptic Ulcer Disease Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding. Alcohol Warning Because aspirin and extended-release dipyridamole capsules contain aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. 5.2 Renal Failure Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. 5.3 Hepatic Insufficiency Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. 5.4 Pregnancy Because aspirin and extended-release dipyridamole capsules contain aspirin, aspirin and extended-release dipyridamole capsules can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid aspirin and extended-release dipyridamole capsules in the third trimester of pregnancy [see Use in Specific Populations (8.1)]. Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m2 basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of aspirin and extended-release dipyridamole capsules. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of aspirin and extended-release dipyridamole capsules in pregnant women. If aspirin and extended-release dipyridamole capsules are used during pregnancy, or if the patient becomes pregnant while taking aspirin and extended-release dipyridamole capsules, inform the patient of the potential hazard to the fetus. 5.5 Coronary Artery Disease Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole. For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications. 5.6 Hypotension Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension. 5.7 General Aspirin and extended-release dipyridamole capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=679
Page 679 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=680
Page 680 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=681
Page 681 of 787
        "generic_name": [
          "ANHYDROUS CITRIC ACID, ASPIRIN, AND SODIUM BICARBONATE"
        "brand_name": [
          "Alka-Seltzer Original"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=682
Page 682 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=683
Page 683 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
      "warnings_and_cautions": [
        "Alcohol warning: If you consume 3 or more alcoholic drinks every day, ask your doctor whether you should take aspirin or other pain reliever/fever reducers. Aspirin may cause stomach bleeding."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=684
Page 684 of 787
        "generic_name": [
          "CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE"
        "brand_name": [
          "Carisoprodol, Aspirin and Codeine Phosphate"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following adverse reactions which have occurred with the administration of the individual products alone may also occur with the use of Carisoprodol, Aspirin and Codeine Phosphate Tablets. The following events have been reported during post-approval individual use of carisoprodol, aspirin, and codeine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Carisoprodol Cardiovascular: Tachycardia, postural hypotension, and facial flushing (see OVERDOSAGE ). Central Nervous System: Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures (see OVERDOSAGE ). Gastrointestinal: Nausea, vomiting, and epigastric discomfort. Hematologic: Leukopenia, pancytopenia. Aspirin The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including both abdominal pain, anorexia, nausea, vomiting, gastritis, and occult bleeding (see WARNINGS, Serious Gastrointestinal Adverse Reactions and PRECAUTIONS, Gastrointestinal Adverse Reactions ).Other adverse reactions associated with the use of aspirin include elevated liver enzymes, rash, pruritus, purpura, intracranial hemorrhage, interstitial nephritis, acute renal failure, and tinnitus. Tinnitus may be a sign of high serum salicylate levels (see OVERDOSAGE ). Codeine Phosphate Nausea, vomiting, constipation, miosis, sedation, dizziness."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=685
Page 685 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=686
Page 686 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=687
Page 687 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Berkley and Jensen Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=688
Page 688 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Anacin ES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=689
Page 689 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Circle K Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=690
Page 690 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Value Pharma Aspirin Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=691
Page 691 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Extra Strength Headache Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=692
Page 692 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "pain relief aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=693
Page 693 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=694
Page 694 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=695
Page 695 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspir Low"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=696
Page 696 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=697
Page 697 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Good Sense aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=698
Page 698 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "aspirin Regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=699
Page 699 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=700
Page 700 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=701
Page 701 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin 81 mg Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=702
Page 702 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin, and Caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, Aspirin, and Caffeine Capsules, USP may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules, USP exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, Aspirin, and Caffeine Capsules, USP may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of Butalbital, Aspirin, and Caffeine Capsules, USP. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=703
Page 703 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Enteric Coated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=704
Page 704 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Butalbital, aspirin, and caffeine"
 
      "drug_interactions": [
        "Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. Butalbital, aspirin, and caffeine capsules may enhance the effects of: Oral anticoagulants, causing bleeding by inhibiting prothrombin formation in the liver and displacing anticoagulants from plasma protein binding sites. Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of butalbital, aspirin, and caffeine capsules exceeds maximum recommended daily dosage. 6-mercaptopurine and methotrexate, causing bone marrow toxicity and blood dyscrasias by displacing these drugs from secondary binding sites, and, in the case of methotrexate, also reducing its excretion. Non-steroidal anti-inflammatory agents, increasing the risk of peptic ulceration and bleeding by contributing additive effects. Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Butalbital, aspirin, and caffeine capsules may diminish the effects of: Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites."
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine capsules. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=705
Page 705 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Good Neighbor Pharmacy Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=706
Page 706 of 787
        "generic_name": [
          "BUTALBITAL, ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Butalbital, Aspirin and Caffeine"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS The most frequent adverse reactions are drowsiness and dizziness. Less frequent adverse reactions are lightheadedness and gastrointestinal disturbances including nausea, vomiting, and flatulence. A single incidence of bone marrow suppression has been reported with the use of butalbital, aspirin, and caffeine. Several cases of dermatological reactions including toxic epidermal necrolysis and erythema multiforme have been reported. To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001, or the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=707
Page 707 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=708
Page 708 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, POVIDONE-IODINE, ACETAMINOPHEN, ASPIRIN, DIPHENHYDRAMINE HYDROCHLORIDE, IBUPROFEN, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE"
        "brand_name": [
          "Mountain Series Weekender Medical"
 
      "warnings_and_cautions": [
        "Warnings Do not use if allergic to iodine in the eyes For external use only Ask a doctor before use if injuries are deep or puncture wounds serious burns Stop use and ask a doctor if redness, irritation, swelling or pain persists or increases infection occurs Avoid pooling beneath patient Keep out of reach of children. In case of accidental ingestion, seek professionalassistance or consult a poison control center immediately."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=709
Page 709 of 787
        "generic_name": [
          "CARISOPRODOL AND ASPIRIN"
        "brand_name": [
          "Carisoprodol and Aspirin"
 
      "drug_interactions": [
        "Drug Interactions Clinically important interactions may occur when certain drugs are administered concomitantly with aspirin or aspirin-containing drugs. 1. Oral Anticoagulants-By interfering with platelet function or decreasing plasma prothrombin concentration, aspirin enhances the potential for bleeding in patients on anticoagulants. 2. Methotrexate-aspirin enhances the toxic effects of this drug. 3. Probenecid and Sulfinpyrazone-large doses of aspirin reduce the uricosuric effect of both drugs. Renal excretion of salicylate may also be reduced. 4. Oral Antidiabetic Drugs-enhancement of hypoglycemia may occur. 5. Antacids-to the extent that they raise urinary pH, antacids may substantially decrease plasma salicylate concentrations; conversely, their withdrawal can result in a substantial increase. 6. Ammonium Chloride-this and other drugs that acidify a relatively alkaline urine can elevate plasma salicylate concentrations. 7. Ethyl Alcohol-enhanced aspirin-induced fecal blood loss has been reported. 8. Corticosteroids-salicylate plasma levels may be decreased when adrenal corticosteroids are given, and may be increased substantially when they are discontinued."
      "adverse_reactions": [
        "ADVERSE REACTIONS If severe reactions occur, discontinue Carisoprodol and Aspirin Tablets and initiate appropriate symptomatic and supportive therapy. The following side effects which have occurred with the administration of the individual ingredients alone may also occur with the combination. Carisoprodol: Central Nervous System: Drowsiness is the most frequent complaint and along with other CNS effects may require dosage reduction. Observed less frequently are dizziness, vertigo and ataxia. Tremor, agitation, irritability, headache, depressive reactions, syncope and insomnia have been infrequent or rare. Idiosyncratic: Idiosyncratic reactions are very rare. They are usually seen within the period of the first to fourth dose in patients having had no previous contact with the drug (see WARNINGS). Allergic: Skin rash erythema multiforme, pruritus, eosinophilia and fixed drug eruptions with cross-reaction to meprobamate have been reported. If allergic reactions occur, discontinue Carisoprodol and Aspirin Tablets and treat symptomatically. In evaluating possible allergic reactions, also consider allergy to excipients. Cardiovascular: Tachycardia, postural hypotension and facial flushing. Gastrointestinal: Nausea, vomiting, epigastric distress and hiccup. Hematologic: No serious blood dyscrasias have been attributed to carisoprodol alone. Leukopenia and pancytopenia have been reported, very rarely, in situations in which other drugs or viral infections may have been responsible. Aspirin: The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including nausea, vomiting, gastritis, occult bleeding, constipation and diarrhea. Gastric erosion, angioedema, asthma rash, pruritus and urticaria have been reported less commonly. Tinnitus is a sign of high serum salicylate levels (see OVERDOSAGE). Aspirin Intolerance: Allergic type reactions in aspirin-sensitive individuals may involve the respiratory tract or the skin. Symptoms of the former range from rhinorrhea and shortness of breath to severe asthma, and the latter may consist of urticaria, edema, rash or angioedema (giant hives). These may occur independently or in combination."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=710
Page 710 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Smart Sense Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=711
Page 711 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=712
Page 712 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "CAREALL Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=713
Page 713 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=714
Page 714 of 787
        "generic_name": [
          "ASPIRIN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE BITARTRATE"
        "brand_name": [
          "Effervescent Cold Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=715
Page 715 of 787
        "generic_name": [
          "ASPIRIN AND DIPYRIDAMOLE"
        "brand_name": [
          "Aggrenox"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS No pharmacokinetic drug-drug interaction studies were conducted with AGGRENOX capsules. The following information was obtained from the literature. Co-administration with anti-coagulants or NSAIDS can increase risk of bleeding (7.4, 7.10) Decreased renal function can occur with co-administration with NSAIDS (7.10) 7.1 Adenosine Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. 7.2 Angiotensin Converting Enzyme (ACE) Inhibitors Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. 7.3 Acetazolamide Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. 7.4 Anticoagulant Therapy (heparin and warfarin) Patients on anticoagulation therapy are at increased risk for bleeding because of drug-drug interactions and effects on platelets. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. 7.5 Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. 7.6 Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. 7.7 Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. 7.8 Diuretics The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. 7.9 Methotrexate Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired. 7.10 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function. 7.11 Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. 7.12 Uricosuric Agents (probenecid and sulfinpyrazone) Salicylates antagonize the uricosuric action of uricosuric agents."
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: Hypersensitivity [ see Contraindications (4.1) ]. Allergy [ see Contraindications (4.2) ]. Risk of Bleeding [ see Warnings and Precautions (5.1) ]. The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea (6) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The efficacy and safety of AGGRENOX was established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either AGGRENOX, aspirin, ER-DP, or placebo [ see Clinical Studies (14) ]; primary endpoints included stroke (fatal or nonfatal) and death from all causes. This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization. Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with AGGRENOX where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety. Table 1 Incidence of Adverse Events in ESPS2* Individual Treatment Group Body System/Preferred Term AGGRENOX ER-DP Alone ASA Alone Placebo * Reported by >=1% of patients during AGGRENOX treatment where the incidence was greater than in those treated with placebo. Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID NOS = not otherwise specified. Total Number of Patients 1650 1654 1649 1649 Total Number (%) of Patients With at Least One On-Treatment Adverse Event 1319 (80%) 1305 (79%) 1323 (80%) 1304 (79%) Central and Peripheral Nervous System Disorders Headache 647 (39%) 634 (38%) 558 (34%) 543 (33%) Convulsions 28 (2%) 15 (1%) 28 (2%) 26 (2%) Gastrointestinal System Disorders Dyspepsia 303 (18%) 288 (17%) 299 (18%) 275 (17%) Abdominal Pain 289 (18%) 255 (15%) 262 (16%) 239 (14%) Nausea 264 (16%) 254 (15%) 210 (13%) 232 (14%) Diarrhea 210 (13%) 257 (16%) 112 (7%) 161 (10%) Vomiting 138 (8%) 129 (8%) 101 (6%) 118 (7%) Hemorrhage Rectum 26 (2%) 22 (1%) 16 (1%) 13 (1%) Melena 31 (2%) 10 (1%) 20 (1%) 13 (1%) Hemorrhoids 16 (1%) 13 (1%) 10 (1%) 10 (1%) GI Hemorrhage 20 (1%) 5 (0%) 15 (1%) 7 (0%) Body as a Whole - General Disorders Pain 105 (6%) 88 (5%) 103 (6%) 99 (6%) Fatigue 95 (6%) 93 (6%) 97 (6%) 90 (5%) Back Pain 76 (5%) 77 (5%) 74 (4%) 65 (4%) Accidental Injury 42 (3%) 24 (1%) 51 (3%) 37 (2%) Malaise 27 (2%) 23 (1%) 26 (2%) 22 (1%) Asthenia 29 (2%) 19 (1%) 17 (1%) 18 (1%) Syncope 17 (1%) 13 (1%) 16 (1%) 8 (0%) Psychiatric Disorders Amnesia 39 (2%) 40 (2%) 57 (3%) 34 (2%) Confusion 18 (1%) 9 (1%) 22 (1%) 15 (1%) Anorexia 19 (1%) 17 (1%) 10 (1%) 15 (1%) Somnolence 20 (1%) 13 (1%) 18 (1%) 9 (1%) Musculoskeletal System Disorders Arthralgia 91 (6%) 75 (5%) 91 (6%) 76 (5%) Arthritis 34 (2%) 25 (2%) 17 (1%) 19 (1%) Arthrosis 18 (1%) 22 (1%) 13 (1%) 14 (1%) Myalgia 20 (1%) 16 (1%) 11 (1%) 11 (1%) Respiratory System Disorders Coughing 25 (2%) 18 (1%) 32 (2%) 21 (1%) Upper Respiratory Tract Infection 16 (1%) 9 (1%) 16 (1%) 14 (1%) Cardiovascular Disorders, General Cardiac Failure 26 (2%) 17 (1%) 30 (2%) 25 (2%) Platelet, Bleeding and Clotting Disorders Hemorrhage NOS 52 (3%) 24 (1%) 46 (3%) 24 (1%) Epistaxis 39 (2%) 16 (1%) 45 (3%) 25 (2%) Purpura 23 (1%) 8 (0%) 9 (1%) 7 (0%) Neoplasm Neoplasm NOS 28 (2%) 16 (1%) 23 (1%) 20 (1%) Red Blood Cell Disorders Anemia 27 (2%) 16 (1%) 19 (1%) 9 (1%) Discontinuation due to adverse events in ESPS2 was 25% for AGGRENOX, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2) Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of >=1% in the AGGRENOX Group Treatment Groups AGGRENOX ER-DP ASA Placebo Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID Total Number of Patients 1650 1654 1649 1649 Patients with at least one Adverse Event that led to treatment discontinuation 417 (25%) 419 (25%) 318 (19%) 352 (21%) Headache 165 (10%) 166 (10%) 57 (3%) 69 (4%) Dizziness 85 (5%) 97 (6%) 69 (4%) 68 (4%) Nausea 91 (6%) 95 (6%) 51 (3%) 53 (3%) Abdominal Pain 74 (4%) 64 (4%) 56 (3%) 52 (3%) Dyspepsia 59 (4%) 61 (4%) 49 (3%) 46 (3%) Vomiting 53 (3%) 52 (3%) 28 (2%) 24 (1%) Diarrhea 35 (2%) 41 (2%) 9 (<1%) 16 (<1%) Stroke 39 (2%) 48 (3%) 57 (3%) 73 (4%) Transient Ischemic Attack 35 (2%) 40 (2%) 26 (2%) 48 (3%) Angina Pectoris 23 (1%) 20 (1%) 16 (<1%) 26 (2%) Headache was most notable in the first month of treatment. Other Adverse Events Adverse reactions that occurred in less than 1% of patients treated with AGGRENOX in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below. Body as a Whole : Allergic reaction, fever Cardiovascular : Hypotension Central Nervous System : Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage Gastrointestinal : Gastritis, ulceration and perforation Hearing and Vestibular Disorders : Tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism Heart Rate and Rhythm Disorders : Tachycardia, palpitation, arrhythmia, supraventricular tachycardia Liver and Biliary System Disorders : Cholelithiasis, jaundice, hepatic function abnormal Metabolic and Nutritional Disorders : Hyperglycemia, thirst Platelet, Bleeding and Clotting Disorders : Hematoma, gingival bleeding Psychiatric Disorders : Agitation Reproductive : Uterine hemorrhage Respiratory : Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edema Special Senses Other Disorders : Taste loss Skin and Appendages Disorders : Pruritus, urticaria Urogenital : Renal insufficiency and failure, hematuria Vascular (Extracardiac) Disorders : Flushing Laboratory Changes Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm3. 6.2 Post-Marketing Experience The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to AGGRENOX. Body as a Whole : Hypothermia, chest pain Cardiovascular : Angina pectoris Central Nervous System : Cerebral edema Fluid and Electrolyte : Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia Gastrointestinal : Pancreatitis, Reye syndrome, hematemesis Hearing and Vestibular Disorders : Hearing loss Immune System Disorders : Hypersensitivity, acute anaphylaxis, laryngeal edema Liver and Biliary System Disorders : Hepatitis, hepatic failure Musculoskeletal : Rhabdomyolysis Metabolic and Nutritional Disorders : Hypoglycemia, dehydration Platelet, Bleeding and Clotting Disorders : Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia Reproductive : Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding Respiratory : Tachypnea, dyspnea Skin and Appendages Disorders : Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematoma Urogenital : Interstitial nephritis, papillary necrosis, proteinuria Vascular (Extracardiac Disorders) : Allergic vasculitis Other adverse events : anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis."
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS The risk of GI bleeding is increased, especially in patients who are heavy alcohol users, have a history of peptic ulcer, or have coagulation abnormalities due to liver disease or vitamin K deficiency (5.1) As with other antiplatelets, there is a risk of intracranial hemorrhage (5.1) Avoid use in patients with severe hepatic or renal insufficiency (5.2, 5.3) Can cause fetal harm when administered to a pregnant woman, especially in the third trimester (5.4) 5.1 Risk of Bleeding Intracranial Hemorrhage In ESPS2 the incidence of intracranial hemorrhage was 0.6% in the AGGRENOX group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups. Coagulation Abnormalities Even low doses of aspirin can inhibit platelet function leading to an increase in bleeding time. This can adversely affect patients with inherited or acquired (liver disease or vitamin K deficiency) bleeding disorders [ see Drug Interactions (7.4) ]. Gastrointestinal (GI) Side Effects GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur. In ESPS2 the incidence of gastrointestinal bleeding was 4.1% in the AGGRENOX group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups. Peptic Ulcer Disease Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding. Alcohol Warning Because AGGRENOX contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. 5.2 Renal Failure Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.3 Hepatic Insufficiency Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 5.4 Pregnancy Because AGGRENOX contains aspirin, AGGRENOX can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid AGGRENOX in the third trimester of pregnancy [ see Use in Specific Populations (8.1) ]. Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m2 basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of AGGRENOX. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of AGGRENOX in pregnant women. If AGGRENOX is used during pregnancy, or if the patient becomes pregnant while taking AGGRENOX, inform the patient of the potential hazard to the fetus. 5.5 Coronary Artery Disease Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole. For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications. 5.6 Hypotension Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension. 5.7 General AGGRENOX capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=716
Page 716 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=717
Page 717 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Uncoated Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=718
Page 718 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ENTERIC COATED ASPIRIN Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=719
Page 719 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=720
Page 720 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=721
Page 721 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Healthy Accents migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=722
Page 722 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=723
Page 723 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "good sense aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=724
Page 724 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "equate aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=725
Page 725 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=726
Page 726 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=727
Page 727 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin 81 mg Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=728
Page 728 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=729
Page 729 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=730
Page 730 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=731
Page 731 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin EC"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=732
Page 732 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin enteric safety coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=733
Page 733 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=734
Page 734 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN EXTRA STRENGTH"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=735
Page 735 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "good sense migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=736
Page 736 of 787
        "generic_name": [
          "ACETAMINOPHEN SALICYLAMIDE ASPIRIN"
        "brand_name": [
          "Zee Pain Aid"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=737
Page 737 of 787
        "generic_name": [
          "ASPIRIN AND DIPYRIDAMOLE"
        "brand_name": [
          "Aggrenox"
 
      "drug_interactions": [
        "7 DRUG INTERACTIONS Co-administration with anticoagulants, antiplatelets, or NSAIDS can increase risk of bleeding (7.1) Decreased renal function can occur with co-administration with NSAIDS (7.1) 7.1 Drug Interaction Study Information Obtained From Literature Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Adenosine Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. Angiotensin Converting Enzyme (ACE) Inhibitors Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. Acetazolamide Patients taking AGGRENOX in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. Anticoagulants and Antiplatelets Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. Anticonvulsants The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Beta Blockers Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Cholinesterase Inhibitors The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. Diuretics Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired. Methotrexate The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. Oral Hypoglycemics Salicylates antagonize the uricosuric action of uricosuric agents. Uricosuric Agents (probenecid and sulfinpyrazone)"
      "adverse_reactions": [
        "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: Hypersensitivity [ ]. see Contraindications (4.1) Allergy [ ]. see Contraindications (4.2) Risk of Bleeding [ ]. see Warnings and Precautions (5.1) The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea (6) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The efficacy and safety of AGGRENOX was established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either AGGRENOX, aspirin, ER-DP, or placebo [ ]; primary endpoints included stroke (fatal or nonfatal) and death from all causes. see Clinical Studies (14) This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization. Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with AGGRENOX where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety. Table 1 Incidence of Adverse Events in ESPS2* Individual Treatment Group Body System/Preferred Term AGGRENOX ER-DP Alone ASA Alone Placebo * Reported by >=1% of patients during AGGRENOX treatment where the incidence was greater than in those treated with placebo. Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID NOS = not otherwise specified. Total Number of Patients 1650 1654 1649 1649 Total Number (%) of Patients With at Least One On-Treatment Adverse Event 1319 (80%) 1305 (79%) 1323 (80%) 1304 (79%) Central and Peripheral Nervous System Disorders Headache 647 (39%) 634 (38%) 558 (34%) 543 (33%) Convulsions 28 (2%) 15 (1%) 28 (2%) 26 (2%) Gastrointestinal System Disorders Dyspepsia 303 (18%) 288 (17%) 299 (18%) 275 (17%) Abdominal Pain 289 (18%) 255 (15%) 262 (16%) 239 (14%) Nausea 264 (16%) 254 (15%) 210 (13%) 232 (14%) Diarrhea 210 (13%) 257 (16%) 112 (7%) 161 (10%) Vomiting 138 (8%) 129 (8%) 101 (6%) 118 (7%) Hemorrhage Rectum 26 (2%) 22 (1%) 16 (1%) 13 (1%) Melena 31 (2%) 10 (1%) 20 (1%) 13 (1%) Hemorrhoids 16 (1%) 13 (1%) 10 (1%) 10 (1%) GI Hemorrhage 20 (1%) 5 (0%) 15 (1%) 7 (0%) Body as a Whole - General Disorders Pain 105 (6%) 88 (5%) 103 (6%) 99 (6%) Fatigue 95 (6%) 93 (6%) 97 (6%) 90 (5%) Back Pain 76 (5%) 77 (5%) 74 (4%) 65 (4%) Accidental Injury 42 (3%) 24 (1%) 51 (3%) 37 (2%) Malaise 27 (2%) 23 (1%) 26 (2%) 22 (1%) Asthenia 29 (2%) 19 (1%) 17 (1%) 18 (1%) Syncope 17 (1%) 13 (1%) 16 (1%) 8 (0%) Psychiatric Disorders Amnesia 39 (2%) 40 (2%) 57 (3%) 34 (2%) Confusion 18 (1%) 9 (1%) 22 (1%) 15 (1%) Anorexia 19 (1%) 17 (1%) 10 (1%) 15 (1%) Somnolence 20 (1%) 13 (1%) 18 (1%) 9 (1%) Musculoskeletal System Disorders Arthralgia 91 (6%) 75 (5%) 91 (6%) 76 (5%) Arthritis 34 (2%) 25 (2%) 17 (1%) 19 (1%) Arthrosis 18 (1%) 22 (1%) 13 (1%) 14 (1%) Myalgia 20 (1%) 16 (1%) 11 (1%) 11 (1%) Respiratory System Disorders Coughing 25 (2%) 18 (1%) 32 (2%) 21 (1%) Upper Respiratory Tract Infection 16 (1%) 9 (1%) 16 (1%) 14 (1%) Cardiovascular Disorders, General Cardiac Failure 26 (2%) 17 (1%) 30 (2%) 25 (2%) Platelet, Bleeding and Clotting Disorders Hemorrhage NOS 52 (3%) 24 (1%) 46 (3%) 24 (1%) Epistaxis 39 (2%) 16 (1%) 45 (3%) 25 (2%) Purpura 23 (1%) 8 (0%) 9 (1%) 7 (0%) Neoplasm Neoplasm NOS 28 (2%) 16 (1%) 23 (1%) 20 (1%) Red Blood Cell Disorders Anemia 27 (2%) 16 (1%) 19 (1%) 9 (1%) Discontinuation due to adverse events in ESPS2 was 25% for AGGRENOX, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2) Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of >=1% in the AGGRENOX Group Treatment Groups AGGRENOX ER-DP ASA Placebo Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID Total Number of Patients 1650 1654 1649 1649 Patients with at least one Adverse Event that led to treatment discontinuation 417 (25%) 419 (25%) 318 (19%) 352 (21%) Headache 165 (10%) 166 (10%) 57 (3%) 69 (4%) Dizziness 85 (5%) 97 (6%) 69 (4%) 68 (4%) Nausea 91 (6%) 95 (6%) 51 (3%) 53 (3%) Abdominal Pain 74 (4%) 64 (4%) 56 (3%) 52 (3%) Dyspepsia 59 (4%) 61 (4%) 49 (3%) 46 (3%) Vomiting 53 (3%) 52 (3%) 28 (2%) 24 (1%) Diarrhea 35 (2%) 41 (2%) 9 (<1%) 16 (<1%) Stroke 39 (2%) 48 (3%) 57 (3%) 73 (4%) Transient Ischemic Attack 35 (2%) 40 (2%) 26 (2%) 48 (3%) Angina Pectoris 23 (1%) 20 (1%) 16 (<1%) 26 (2%) Headache was most notable in the first month of treatment. Adverse reactions that occurred in less than 1% of patients treated with AGGRENOX in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below. Other Adverse Events : Allergic reaction, fever Body as a Whole : Hypotension Cardiovascular : Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage Central Nervous System : Gastritis, ulceration and perforation Gastrointestinal : Tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism Hearing and Vestibular Disorders : Tachycardia, palpitation, arrhythmia, supraventricular tachycardia Heart Rate and Rhythm Disorders : Cholelithiasis, jaundice, hepatic function abnormal Liver and Biliary System Disorders : Hyperglycemia, thirst Metabolic and Nutritional Disorders : Hematoma, gingival bleeding Platelet, Bleeding and Clotting Disorders : Agitation Psychiatric Disorders : Uterine hemorrhage Reproductive : Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edema Respiratory : Taste loss Special Senses Other Disorders : Pruritus, urticaria Skin and Appendages Disorders : Renal insufficiency and failure, hematuria Urogenital : Flushing Vascular (Extracardiac) Disorders Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x10 /mm . Laboratory Changes 6 3 6.2 Post-Marketing Experience The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to AGGRENOX. : Hypothermia, chest pain Body as a Whole : Angina pectoris Cardiovascular : Cerebral edema Central Nervous System : Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia Fluid and Electrolyte : Pancreatitis, Reye syndrome, hematemesis Gastrointestinal : Hearing loss Hearing and Vestibular Disorders : Hypersensitivity, acute anaphylaxis, laryngeal edema Immune System Disorders : Hepatitis, hepatic failure Liver and Biliary System Disorders : Rhabdomyolysis Musculoskeletal : Hypoglycemia, dehydration Metabolic and Nutritional Disorders : Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia Platelet, Bleeding and Clotting Disorders : Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding Reproductive : Tachypnea, dyspnea Respiratory : Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematoma Skin and Appendages Disorders : Interstitial nephritis, papillary necrosis, proteinuria Urogenital : Allergic vasculitis Vascular (Extracardiac Disorders) : anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis. Other Adverse Events"
      "warnings_and_cautions": [
        "5 WARNINGS AND PRECAUTIONS AGGRENOX increases the risk of bleeding (5.1) Avoid use in patients with severe hepatic or renal insufficiency , (5.2 5.3) Can cause fetal harm when administered to a pregnant woman, especially in the third trimester (5.4) 5.1 Risk of Bleeding AGGRENOX increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs) [ ]. see Drug Interactions (7.1) In ESPS2 the incidence of intracranial hemorrhage was 0.6% in the AGGRENOX group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups. Intracranial Hemorrhage GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur. Gastrointestinal (GI) Side Effects In ESPS2 the incidence of gastrointestinal bleeding was 4.1% in the AGGRENOX group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups. Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding. Peptic Ulcer Disease Because AGGRENOX contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. Alcohol Warning 5.2 Renal Failure Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [ ]. see Use in Specific Populations and Clinical Pharmacology (8.6) (12.3) 5.3 Hepatic Insufficiency Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [ ]. see Use in Specific Populations and Clinical Pharmacology (8.6) (12.3) 5.4 Pregnancy Because AGGRENOX contains aspirin, AGGRENOX can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid AGGRENOX in the third trimester of pregnancy [ ]. see Use in Specific Populations (8.1) Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of AGGRENOX. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of AGGRENOX in pregnant women. If AGGRENOX is used during pregnancy, or if the patient becomes pregnant while taking AGGRENOX, inform the patient of the potential hazard to the fetus. 2 2 5.5 Coronary Artery Disease Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole. For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications. 5.6 Hypotension Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension. 5.7 General AGGRENOX capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=738
Page 738 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "healthy accents aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=739
Page 739 of 787
        "generic_name": [
          "ASPIRIN 81 MG"
        "brand_name": [
          "Pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=740
Page 740 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "MINIPRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=741
Page 741 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "headache relief added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=742
Page 742 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Enteric Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=743
Page 743 of 787
        "generic_name": [
          "ACETAMINOPHEN, CAFFEINE, ASPIRIN"
        "brand_name": [
          "Pain Stoppers Extra"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=744
Page 744 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "ConRx pain Reliever"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=745
Page 745 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric coated aspirin Regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=746
Page 746 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=747
Page 747 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "migraine formula"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=748
Page 748 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Regular Strength Tri-Buffered Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=749
Page 749 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Leader Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=750
Page 750 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=751
Page 751 of 787
        "generic_name": [
          "ASPIRIN AND CAFFEINE"
        "brand_name": [
          "Regular Strength Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=752
Page 752 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "dg health headache relief added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=753
Page 753 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "CAREALL Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=754
Page 754 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "leader headache formula added strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=755
Page 755 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=756
Page 756 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=757
Page 757 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=758
Page 758 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=759
Page 759 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, AND CAFFEINE"
        "brand_name": [
          "Goodys"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=760
Page 760 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=761
Page 761 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=762
Page 762 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, SALICYLAMIDE AND CAFFEINE"
        "brand_name": [
          "Medi First Pain Relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=763
Page 763 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose Safety Coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=764
Page 764 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=765
Page 765 of 787
        "generic_name": [
          "ENTERIC ASPIRIN"
        "brand_name": [
          "Enteric Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=766
Page 766 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Ecotrin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=767
Page 767 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Solves - aspirin Cherry"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=768
Page 768 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, BENZALKONIUM CHLORIDE, LIDOCAINE, BACITRACIN ZINC,NEOMYCIN SULFATE,POLYMYXIN B SULFATE, POVIDONE-IODINE, WATER, ALCOHOL, ASPIRIN, IBUPROFEN, ACETAMINOPHEN, BENZOCAINE, ALCOHOL"
        "brand_name": [
          "GFA First Aid 75 Person Metal Case"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=769
Page 769 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Health Mart Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=770
Page 770 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=771
Page 771 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=772
Page 772 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "Headache Relief Extra Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=773
Page 773 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=774
Page 774 of 787
        "generic_name": [
          "ANHYDROUS CITRIC ACID, ASPIRIN, AND SODIUM BICARBONATE"
        "brand_name": [
          "Alka-Seltzer"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=775
Page 775 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Chewable Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=776
Page 776 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Enteric Coated Aspirin Regular Strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=777
Page 777 of 787
        "generic_name": [
          "ACETAMINOPHEN, ASPIRIN, CAFFEINE"
        "brand_name": [
          "equate migraine relief"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=778
Page 778 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Sunmark aspirin adult low strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=779
Page 779 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "ASPIRIN"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=780
Page 780 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "smart sense aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=781
Page 781 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Adult Low Dose Aspirin"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=782
Page 782 of 787
        "generic_name": [
          "BENZALKONIUM CHLORIDE, LIDOCAINE, WATER, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, WATER, ISOPROPYL ALCOHOL, BENZOCAINE, ALCOHOL, ASPIRIN"
        "brand_name": [
          "ARC FIRST AID Contains 1000 PIECES"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=783
Page 783 of 787
        "generic_name": [
          "ASPIRIN, IBUPROFEN, ACETAMINOPHEN, ALCOHOL, BENZALKONIUM CHLORIDE, BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, BENZALKONIUM CHLORIDE, LIDOCAINE, BENZOCAINE, ALCOHOL"
        "brand_name": [
          "Ready America First Aid Outdoor- 107 Pieces"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=784
Page 784 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Low Dose"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=785
Page 785 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "smart health aspirin regular strength"
 
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Aspirin&limit=1&skip=786
Page 786 of 787
        "generic_name": [
          "ASPIRIN"
        "brand_name": [
          "Aspirin Thin coated"
 
 
 
--------------------------------------------------------------------------------------------------------------------
